

REFERENCES FOR DRUG DOSAGE GUIDELINES FOR INFANTS AND OLDER CHILDREN

1. Hughes HK et al (eds) *The Harriet Lane Handbook—21st edition*. Elsevier Inc 2017
2. Barst RJ, Ivy DD, Gaitan G et al. A randomized, double blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment naïve children with pulmonary arterial hypertension. *Circulation* 2012;125:324-34
3. Hayashi AH, Lau HY, Gillis DA. Topical sucrafate: effective therapy for the management of resistant peristomal and perineal excoriation. *J Pediatr Surg* 1991;26:1279-81
4. Compendium of Pharmaceuticals and Specialties (CPS) [Internet]. Ottawa (ON): Canadian Pharmacy Association. Accessed Apr 11,2025. Available from: www.e-cps.ca
5. Bradley JS (ed). *Nelson's Pediatric Antimicrobial Therapy--20th Edition*. American Academy of Pediatrics. 2014
6. American Academy of Pediatrics. Kimberlin DW, Barnett ED, Lynfield R eds. 2024 Red Book Report of the Committee on Infectious Diseases—33rd Edition. Elk Grove Village IL: 2024
7. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? *Neurology* 1997;48:1100-3
8. Product Monograph: KINERET anakinra solution for injection. Swedish Orphan Biovitrum AB imported by C.R.I. Dundas, Ontario 2018
9. Aronoff GR, Bennett WM (eds) *Drug Prescribing in Renal Failure*, 5th edition 2007. American College of Physicians.
10. Tighe M, Afzal NA, Bevan A et al. Pharmacological treatment of children with gastro-oesophageal reflux. *Cochrane Database Syst Rev* 2014;CD008550
11. Metzger D. BCCH Endocrine Handout: Adrenal Steroid Therapy and Weaning. Oct 1, 2020. Available from: <https://www.bccchildrens.ca/sites/g/files/qpdaav156/files/2024-12/steroid-therapy-weaning.pdf>
12. Choong C, Kissoon N. Vasopressin in pediatric shock and cardiac arrest. *Pediatr Crit Care Med* 2008;9:372-9
13. Kim SY, Dabb AA, Glenn DJ et al. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. *Pediatr Blood Cancer* 2008;50:779-783
14. Vondracek P, Oslejskova H, Kepak T et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. *Eur J Paediatr Neurol* 2009;13: 332-6
15. Saul JP, Scott WA, Brown S et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. *Circulation* 2005;112:3470-3477
16. Druka D, Grey VL, Ferland G et al. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. *J Cyst Fibros* 2008;7:457-459
17. Money D, Tulloch K, Boucoiran I et al. BC Guidelines for care of HIV positive pregnant women and interventions to reduce perinatal transmission. 2013 Available from: <http://www.bcwomens.ca/Professional-Resources-site/Documents/Oak%20Tree/BCHIVinpregnancyguidelinesFINALAug72014.pdf>
18. Jan JE, Wasdell MB, Reiter RJ et al. Melatonin therapy of pediatric sleep disorders: recent advances, why it works, who are the candidates and how to treat. *Curr Pediatr Rev* 2007;3:21-224
19. Poison Management Manual 2024. BC Drug and Poison Information Centre, Vancouver (BC). Available from: <http://www.dpic.org/content/new-poison-management-manual>
20. Glorieux FH. Osteogenesis Imperfecta. *Best Pract Res Clin Rheumatol* 2008;22:85-100
21. Li, BU, Lefevre F. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. *J Pediatr Gastroenterol Nutr* 2008;47:379-93
22. CATMAT malaria guidelines. Chapter 7-Treatment of malaria: Canadian recommendations for the prevention and treatment of malaria. Updated 2019. Accessed Apr 28, 2022 <https://www.canada.ca/en/public-health/services/catmat/canadian-recommendations-prevention-treatment-malaria.html>
23. Hamida FB, Esper I, Compagnon M et al. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. *Nephron* 1993;63:258-262
24. Jongerius PH, van den Hoogen FJ, van Limbeek J et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. *Pediatrics* 2004;114:620-7
25. O'Brien L, Taddio A, Lyszkiewicz DA et al. A critical review of topical local anesthetic amethocaine (Ametop) for pediatric pain. *Pediatr Drugs* 2005;7:41-54
26. Brunner HI, Ruperto N, Ramanan AV et al. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. *Rheumatology* 2024;63:2535-46
27. Koletzko S, Jones NL, Goodman KJ et al. Evidence-Based Guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children. *J Pediatr Gastroenterol Nutr* 2011;53:230-43
28. Hanly JG, Fitzgerald MX. Meconium ileus equivalent in older patients with cystic fibrosis. *Br Med J* 1983; 286:1411-3
29. Seiklay MG. Hypertension in children. An update on treatment strategies. *Curr Opin Pediatr* 2007;19:170-177
30. Yang C and Montgomery M. Dornase alfa for cystic fibrosis. *Cochrane Database Syst Rev* 2021 Mar 18;3:CD001127
31. Adelson PD, Bratton SL, Carney NA et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric traumatic brain injury. *Pediatr Crit Care Med* 2003;4:S40-44
32. Personal communications with relevant Medical Department and Division Heads, BCCH
33. Hassall E, Israel D, Shepherd R et al. Omeprazole for treatment of chronic erosive esophagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements. *J Pediatr* 2000;137:800-7
34. Dawkins TN, Barclay CA, Gardiner RL et al. Safety of intravenous use of ketorolac in infants following cardiothoracic surgery. *Cardiol Young* 2009;19:150-108
35. Olivieri NF, Briittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood* 1997; 89:739-761
36. Committee on Nutrition. Aluminum Toxicity in Infants and Children. *Pediatrics* 1996;97:413-416

37. de Caen AR, Berg MD, Chameides L et al. Part 12: Pediatric Advanced Life Support 2015 AHA Guidelines for Cardiopulmonary Resuscitation and Emergency cardiovascular care. *Circulation* 2015;132:S526-42
38. Kibby D, Trinkman H. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature. *Pediatr Blood Cancer* 2024;71:e30831
39. Durkan AM, Keating LE, Vigneux A et al. The use of darbepoetin in infants with chronic renal impairment. *Pediatr Nephrol* 2006;21:694-7
40. Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. *Am J Health-Syst Pharm* 2007;64:1157-62
41. Yoshikawa N, Nakanishi K, Sako M et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. *Kidney Int* 2015; 87:225-232
42. Kadauke S, Myers RM, Li Yet al. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. *J Clin Oncol* 2021;39:920-30
43. Wigjaja NA, Pratama A, Prihaningtyas RA et al. Efficacy oral glutamine to prevent oral mucositis and reduce hospital costs during chemotherapy in children with acute lymphoblastic leukemia. *Asian Pac J Cancer Prev* 2020;21:2117-21
44. Taketomo C (ed). *Pediatric Dosage Handbook*. 28th ed. Lexi Comp Inc. Cleveland; 2021
45. Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE—towards a comprehensive management plan. *Nat Rev Rheumatol* 2011;7:225-33
46. Stockmann C, Sherwin CMT, Zobell JT et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III Fluoroquinolones. *Pediatr Pulmonol* 2013;48:2011-20
47. Lerner G, Kale AS, Warady BA et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 2002;17:933-7
48. BCCH Emergency Department. Algorithm for Diagnosis of Croup Algorithm. March 2012
49. James PJ, Howard RF, Williams DG. The addition of ketamine to a morphine nurse-or patient-controlled analgesia infusion (PCA/NCA) increases analgesic efficacy in children with mucositis pain. *Pediatr Anesthes* 2010;20:805-11
50. Paller AS, Siegfried EC, Eichenfield LF et al. Long-term etanercept in pediatric patients with plaque psoriasis. *J Am Acad Dermatol* 2010;63:762-8
51. Croup: Pharmacologic and Supportive Interventions. UpToDate. Online access November 18, 2021
52. Laer S, Elshoff JP, Meibohm B et al. Development of a safe and effective pediatric dosing regimen based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. *J Am Coll Cardiol* 2005;46:1322-30
53. Van der Bijl P, Roelofse J. Disinhibitory reactions to benzodiazepines: A review. *J Oral Maxillofac Surg* 1991;49:519-523
54. Child Health BC. Provincial Asthma Guideline; Initial Management of Pediatric Asthma Exacerbations. Vancouver, BC: Child Health BC, October 2024. Available at: https://shop.healthcarebc.ca/phsa/BCWH_2/CW%20Campus%20Wide/C-0506-07-63037.pdf
55. Walsh EP, Saul JP, Sholler GF et al. Evaluation of a Staged Treatment Protocol for Rapid Automatic Junctional Tachycardia After Operation for Congenital Heart Disease. *J Am Coll Cardiol* 1997;29:1046-53
56. Cole TS, Riordan A. Vancomycin dosing in children: what is the question? *Arch Dis Child* 2013;98:994-7
57. Greenhill L, Kollins S, Abikoff H et al. Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 2006;45:1284-93
58. Ng E, Loewy AD. Guidelines for vitamin K prophylaxis in newborns. Canadian Pediatric Society Position Statement. *Paediatr Child Health* 2018;23:394-7
59. Clark MB, Keels MA, Slayton RL. Fluoride Use in Caries Prevention in the Primary Care Setting. *Pediatrics* 2020;146:e2020034637
60. Ferguson MA, Flynn JT. Rational use of antihypertensive medication in children. *Pediatr Nephrol* 2013;29:979-988
61. Haberle J, Boddaert N, Burlina A et al. Suggested Guidelines for the diagnosis and management of urea cycle disorders. *Orphanet J Rare Dis* 2012;7:32
62. Thiamine Deficiency. Dynamedex [Internet]. Dynamedex.com. Accessed Mar 14, 2025. Available from www.dynamedex.com/condition/thiamine-deficiency-22#GUID-29895C43-812B-4272-811B-5D2B5143F272
63. Cisapride. Cancelled Post Market. <https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10690>
64. Sathe MN, Patel AS. Update in pediatrics: Focus on fat-soluble vitamins. *Nutrition in Clinical Practice*. 2010; 25(4): 340-346.
65. Bruns LA, Canter CE. Should beta-blockers be used for the chronic treatment of pediatric patients with chronic heart failure? *Pediatr Drugs* 2002;4:771-8
66. Ostman-Smith I, Wettrell G, Riesenfeld T. A Cohort study of childhood Hypertrophic Cardiomyopathy. *J Am Coll Cardiol* 1999;34:1813-22
67. Manufacturer's literature
68. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. *Antimicrob Agents Chemother* 2005;49:4536-45
69. Chrysostomou C, Sanchez de Toledo J, Avolio T et al. Dexmedetomidine use in a pediatric intensive care unit: Can we use it in infants after cardiac surgery? *Pediatr Crit Care Med* 2009;10:654-60
70. Vojinović J, Foeldvari I, Dehoorne J et al. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis. *Rheumatology (Oxford)* 2024;63:140-8
71. Product Monograph Erelzi: Etanercept solution for injection. Sandoz Canada Inc. Boucherville, Quebec 2023
72. Penack O, Marchett M, Ruutu T et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. *Lancet Haematol* 2020;7:e157-67
73. Equi A, Balfour-Lynn IM, Bush A et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo controlled crossover trial. *Lancet* 2002 ;360:978-84

74. Scheinberg P, Nunez O, Weinstein B et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. *New Engl J Med* 2011;365:430-8
75. Ettenger R, Bartosh S, Choi L et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. *Pediatric Transplantation* 2005;9:780-7
76. Adefurin A, Sammons H, Jacqz-Aigrain E et al. Ciprofloxacin safety in paediatrics: a systematic review. *Arch Dis Child* 2011;96:874-80
77. Lee JH, Lee SH, Oh JH. Minimal effective dosage of recombinant human erythropoietin in spinal surgery. *Clin Orthop Relat Res* 2003;412:71-6
78. Alper A, Pashankar DS. Polyethylene glycol: a game-changer laxative for children. *J Pediatr Gastroenterol Nutr* 2013;57:134-140
79. Evans D, Turnham L, Barbour K et al. Intravenous ketamine sedation for painful oncology procedures. *Pediatr Anesthesia* 2005;15:131-8
80. Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy? *Curr Allergy Asthma Rep* 2008;8:37-44
81. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: double-blind, crossover trial. *Pediatrics* 1987;79:946-52
82. Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. *Clin Pharmacokinet* 2003;42:33-58
83. Elbe D, Black TR, McGrane IR, Choi S (eds) 2023. *Clinical Handbook of Psychotropic Drugs for Children and Adolescents – 5th ed.* Boston, MA: Hogrefe Publishing
84. Carr R, Wasdell MB, Hamilton D et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. *J Pineal Res* 2007;3:351-59
85. Flynn JT, Nahata MC, Mahan Jr JD et al. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. *J Clin Pharmacol* 2006;46:905-916
86. Schulte PFJ. Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring. *Ann Pharmacother* 2006;40:683-8
87. Grond S, Sablotzki A. Clinical pharmacology of tramadol. *Clin Pharmacokinet* 2004;43:879-923
88. Walker J, Maccallum M, Fischer C et al. Sedation using dexmedetomidine in pediatric burn patients. *J Burn Care Res* 2006;27:206-10
89. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. *MMWR Recommendations and Reports* [Internet]. 2024 Aug 8 [cited 2025 Jan 20];73(4):1–126. Available from: <https://www.cdc.gov/mmwr/volumes/73/rr/rr7304a1.htm>
90. Monagle P, Chan AKC, Goldenberg NA et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP evidence-based clinical practice guidelines. *Chest* 2012;141:e737S-e801S
91. Godel JC. Canadian Paediatric Society Position Statement. Vitamin D supplementation: Recommendations for Canadian mothers and infants. *Paediatr Child Health* 2007;12:583-9
92. Tamma PD, Heil EL, Justo JA et al. Infectious diseases society of America 2024 guidance on the treatment of antimicrobial resistant gram-negative infections. *Clin Infect Dis* 2024 Aug 7:ciae403
93. Pappas PG, Kauffman CA, Andes DR et al. Clinical practice guidelines for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. *CID* 2016;62:e1-50
94. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. *Br J Psychiatry* 2009;194:4-9
95. Ketter TA, Wang PW, Chandler RA et al. Dermatology precautions and slower titration yield a low incidence of lamotrigine treatment emergent rash. *J Clin Psychiatry* 2005;66:642-5
96. Bozkurt P. Use of tramadol in children. *Pediatric Anaesthesia* 2005;15:1041-7
97. Nyhan WL. Treatment of the Acute Crisis in Maple Syrup Urine Disease. *Arch Pediatr Adolesc Med* 1998;152:593-8
98. Starting systemic corticosteroid treatment [Internet]. *Australian Asthma Handbook*. National Asthma Council. Accessed Mar 20, 2025. Available from: <https://www.astmahandbook.org.au/acute-asthma/clinical/corticosteroids>
99. Zuppa AF, Mondick JT, Davis L et al. Population pharmacokinetics of ketorolac in neonates and young infants. *Am J Ther* 2009;16:143-6
100. Kimberlin DW, Jester PM, Sanchez PJ et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. *N Engl J Med* 2015; 372:933-43
101. Hazell P, O'Connell D, Heathcote D et al. Tricyclic drugs for depression in children and adolescents. *Cochrane Database Syst Rev* 2002;(2):CD002317
102. Van harten J, Burggraaf K, Danhof M et al. Negligible sublingual absorption of nifedipine. *Lancet* 1987;12:1363-5
103. Murphy JV, Sawasky F, Marquardt KM et al. Deaths in young children receiving nitrazepam. *J Pediatr* 1987;111:145-7
104. Nurko S, Youssef NN, Sabri M et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. *J Pediatr* 2008;153:254-61
105. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics* 2017;140:e20171904
106. Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. *Pediatr Nephrol* 2005;20:631-635
107. Standing J., Tibboel D, Korpela R et al. Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1–12 years. *Pediatr Anesth* 2011;21:316–24
108. Rose JB, Finkel JC, Arquedas-Mohs A et al. Oral tramadol for the treatment of pain of 7-30 days' duration in children. *Anesth Analg* 2003;96:78-81
109. Gordillo R, Spitzer A. The Nephrotic Syndrome. *Pediatr Rev* 2009;30:94-105
110. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. *J Pediatr* 2001;138:S46-5

111. Gillette P, Garson A (eds) *Clinical Pediatric Arrhythmias* 2nd Ed. Philadelphia: WB Saunders: 1999
112. Micromedex. Thomson Healthcare 2025
113. Mantadakis E. Advances in pediatric intravenous iron therapy. *Pediatr Blood Cancer* 2016;63:11-6
114. Nakamura A, Amada N, Haga I et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. *Transplant Proc* 2014;4:592-4
115. Wuhl E, Trivelli A, Picca S et al. Strict blood pressure control and progression to end stage renal failure in children. *New Engl J Med* 2009;361:1639-50
116. Jones GL, Will A, Jackson GH et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. *Br J Haematol* 2015;169: 661-71
117. Young, G et al. Argatroban therapy in pediatric patients requiring non heparin anti-coagulation: An open-label safety, efficacy and pharmacokinetic study. *Pediatr Blood Cancer* 2011;56:1103-9
118. Carbaglu product monograph. Recordati Rare Diseases. France. Nov 6, 2020
119. Ramamoorthy C, Anderson GD, Williams GD et al. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. *Pediatr Anesthesia* 1998;86:283-9
120. Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing Pharmacological treatment of psychotic disorders. *J Clin Psychiatry* 2003;64 Suppl 12:5-19
121. Burks C, Aisner J, Fortner CL et al. Meperidine for the treatment of shaking chills and fever. *Arch Intern Med* 1980;140:483-4
122. Madabushie R, Cox DS, Hossain M et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. *J Clin Pharmacol* 2011;51:19-28
123. Leung AKC, Robson WLM, Kao CP, et al. Treatment of labial fusion with topical estrogen therapy. *Clinical Pediatrics* 2005;44:245-7
124. Deeks ED, Keating GM. Rabbit anti-thymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute allograft rejection. *Drugs* 2009;69: 1483-1512
125. Deeg HJ, Storer BE, Moeckh M et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. *Biol Blood Marrow Transplant* 2006;12:573-84
126. Gao et al. United States Patent. Stable epinephrine suspension formulation with high inhalation delivery efficiency. Amphastar Pharmaceuticals, Feb 5, 2013. #US 8367734B1
127. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Available from: www.ginasthma.org
128. Malignant Hyperthermia Association of the United States: www.mhaus.org
129. Youngster I, Arcavi L, Schechmaster R et al. Medications and glucose-6-phosphate dehydrogenase deficiency. An evidence-based review. *Drug Saf* 2010;33:713-26.
130. Salvadori M, Price V. Preventing and treating infections in children with asplenia or hyposplenia. Canadian Paediatric Society Infectious Diseases and Immunizations Committee. *Paediatr Child Health*. Nov 6, 2019 <https://cps.ca/documents/position/preventing-treating-infections-in-children-with-asplenia> [accessed Apr 11, 2022]
131. Wilschanski M, Munck A, Carrion E et al. ESPEN-ESPHGAN-ECFS guideline on nutrition care for cystic fibrosis. *Clin Nutr* 2024;43:413-445
132. Goldman RD. Codeine for acute cough in children. *Can Fam Physician* 2010;56:1293-4
133. Health Canada Guidance Document: Non-prescription Oral Paediatric the labelling of Cough and Cold Labelling Standard. 2009
134. Kitai I, Demers A-M. Canadian Tuberculosis Standards 7th Edition. 2014. Chapter 9: Pediatric Tuberculosis
135. Trottier ED, Chan K, Allain D et al. Canadian Paediatric Society. Managing an acute asthma exacerbation in children. *Paediatric Child Health* 2021;26:438-9
136. SOGC Clinical Practice Guidelines. Canadian Contraception Consensus, Chapter 3: Emergency Contraception. *J Obstet Gynaecol Can* 2015; 37:S20-28
137. Vaudry W, Ettenger R, Jara P et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplantation recipients. *Am J Transplant* 2009;9:636-43
138. Cassidy JT, Petty RE et al (eds). *Textbook of Pediatric Rheumatology* 7th edition. Philadelphia: Elsevier Saunders: 2016
139. Wong LS, Tymms KE, Buckley NA. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant. *Internal Medicine Journal* 2009;39:379-83
140. Monagle P et al (eds). *Andrew's Pediatric Thromboembolism and Stroke*. 3rd ed. 2006; BC Decker Inc. Hamilton
141. Severin PN, Jacobson JL, Ekhomu O et al. Pharmacological Therapy in Pediatric Cardiology. P1-52. Springer, Cham. 2024. Available at: https://doi.org/10.1007/978-3-030-42937-9_99-1
142. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. *J Clin Oncol* 1999;17:2971-94
143. Canadian Paediatric and Adolescent Gynaecology and Obstetricians (CANPAGO) Committee. SOGC Clinical Practice Guideline No. 313-Menstrual Suppression in Special Circumstances. *J Obstet Gynaecol Can* 2019;41:e7-e17
144. Foerster SR, Canter CE. Pediatric Heart Failure Therapy with β -Adrenoceptor Antagonists. *Pediatr Drugs* 2008;10:125-134
145. Corman SL, Fedutes BA, Culley CM. Atomoxetine: The first non-stimulant for the management of attention-deficit/hyperactivity disorder. *Am J Health Sys Pharm* 2004;16:2391-9
146. Eiland LS, Guest AL. Atomoxetine for the treatment of attention deficit hyperactivity disorder. *Ann Pharmacother* 2004;38:86-90
147. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycaemia in children with type 1 diabetes. *Diabetes Care* 2001;24:643-5
148. Di Iorgi N, Napoli F, Allegri A et al. Diabetes insipidus- Diagnosis and management. *Horm Res Paediatr* 2012;77:69-84

149. Giglia TM, Massicotte MP, Tweddell JS et al. Prevention and treatment of thrombosis in pediatric congenital heart disease. Scientific statement of AHA. *Circulation* 2013;128:2611-703
150. Liu C, Bayer A, Cosgrove SE et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011;52:e18-55
151. Summar M. Current strategies for the management of neonatal urea cycle disorders. *J Pediatr* 2001;138:S30-S39
152. Crandall WV, Mackner LM. Infusion reaction to infliximab in children and adolescents: frequency, outcome and predictive model. *Aliment Pharmacol Ther* 2003;17:75-84
153. Plan B (levonorgestrel) [Health Canada Product Monograph]. Foundation Consumer Healthcare, LLC. Pittsburgh, Pennsylvania. Last revision: April 26, 2018
154. Ormrod D, McClellan K. Topiramate: A review of its use in childhood epilepsy. *Pediatr Drug* 2001;3:293-319
155. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;71:e127-248
156. Onel K, Rumsey DG, Shenoi S. Juvenile Idiopathic Arthritis Treatment Updates. *Rheum Dis Clin North Am* 2021;47:545-563
157. Salcedo J, Cleland K, Bartz D, et al. Society of Family Planning Clinical Recommendations: Emergency contraception. *Contraception* 2023 Jan;109:958
158. Sidhu J, Job S, Singh S et al. The Pharmacokinetic and Pharmacodynamic Consequences of the Co-administration of Lamotrigine and a Combined Oral Contraceptive in Healthy Female Subjects. *Br J Clin Pharmacol* 2006;61:191-9
159. Kerwin EM, Tashkin DP, Murphy TR et al. A dose-ranging study of epinephrine hydrofluoroalkane metered-dose inhaler (Primatene Mist) in subjects with mild to moderate persistent asthma. *J Aerosol Med Pulm Drug Deliv* 2020;33:186-93
160. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto ON; CADDRA, 2020. www.caddra.ca
161. Sotalol (Betapace) Product Monograph. May 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf
162. Riikonen R. Infantile spasms: therapy and outcome. *J Child Neurol* 2004;19:401-404
163. Oliver IN, Grimison P, Chatfield M et al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. *Support Care Cancer* 2013;21:1561-8
164. Rodrigues C, Chiron C, Ounissi M, et al. Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data. *Epilepsy Research* 2019;150:38-45
165. Curry JI, Lander TD, Stringer MD et al. Erythromycin as a prokinetic agent in infants and children. *Aliment Pharmacol Ther* 2001;15:595-603
166. Long R, Avendano M, Kunimoto D. Canadian Tuberculosis Standards 7th Edition. 2013. Chapter 8: Drug-Resistant Tuberculosis
167. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. *Pediatr Infect Dis J* 2011;30:501-5.
168. Choosing wisely Canada – Psychiatry. 13 Tests and treatments to question. <https://choosingwiselycanada.org/recommendation/psychiatry/>
169. Elbe D, Carandang CG. Focus on Ziprasidone: A Review of its use in Child and Adolescent Psychiatry. *J Can Acad Child Adolesc Psychiatry* 2008;17:220-9
170. Child Health BC. Provincial Least Restraint Guideline; Initial Management of Least Restraint in Emergent/Urgent Care and Inpatient Settings. Vancouver, BC: Child Health BC, January 2022
171. BCCH C difficile order set. Approved 2016
172. Rybak MJ, Le J, Lodise TP et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm.* 2020;77:835-63
173. Fung R, Elbe D, Stewart SE. Retrospective Review of Fluvoxamine-Clomipramine Combination Therapy in Obsessive-Compulsive Disorder in Children and Adolescents. *J Can Acad Child Adolesc Psychiatry* 2021;30:150-5
174. Aaronson PM, Belgado BS, Spillane JP et al. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading dose in the ED. *Am J Emerg Med* 2010;29:983-988
175. Mueller EW, Boucher BA. Fosphenytoin: Current place in therapy. *J Pediatr Pharmacol Ther* 2004;9:265-73
176. Emil S, Nguyen T, Sills J et al. Meconium Obstruction in Extremely Low Birth Weight Neonates: Guidelines for Diagnosis and Management. *J Pediatr Surg* 39;5:731-37
177. Cohen-Wolkowicz M, Watt KM, Zhou C et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. *Antimicrob Agents Chemother* 2014;58:2856-65
178. Cies JJ, Shankar V, Schlichting C et al. Pharmacokinetics of piperacillin/tazobactam in critically ill young children. *Pediatr Infect Dis J* 2014;33:168-73
179. Shann F. Drug Doses. Royal Children's Hospital, Melbourne Australia. 15th Edition. 2010
180. Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. *Antimicrob Agents Chemother* 2011;55:5770-9
181. Choi SH, Lee SY, Hwang JY, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. *Pediatr Blood Cancer* 2013;60:82-87
182. Monitto CL, Kost-Byerly S, White E et al. The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study. *Anesth Analg* 2011;113:834-42
183. Escudero C, Carr R, Sanatani S. Overview of antiarrhythmic drug therapy for supraventricular tachycardia. *Prog Pediatr Cardiol* 2013;35:55-63

184. Perez V, Saenz D, Madriz J et al. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica. *Int J Infect Dis* 2011;15:e569-75
185. Greenaway M, Elbe D. Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry. *Journal Can Acad Child Adolesc Psychiatry* 2009;18:250-60.
186. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. *J Am Med Assoc* 2009;302:1765-73
187. Pringsheim T, Panagiotopoulos C, Davidson J et al. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. *Pediatr Child Health* 2011;16:581-9
188. Malik BA, Xie YY, Wine E et al. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. *Can J Gastroenterol* 2011;25:41-5
189. Yang CL, Hicks EA, Mitchell P et al. Canadian Thoracic Society 2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adults. *Can J Respir Crit Care Sleep Med* 2021
190. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. *Am J Clin Dermatol* 2003;4:473-92
191. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2006;43:e1-13
192. Munoz R et al (eds). *Handbook of Pediatric Cardiovascular Drugs*. Second edition. Springer: 2014
193. Fourth Report on Diagnosis, Evaluation and Treatment of High blood pressure in Children and Adolescents. *Pediatrics* 2004;114:555-76
194. Eligard (leuprolide acetate for injectable suspension) [Health Canada Product Monograph]. Tolmar International Ltd. Dublin, Ireland. Last revision: September 20, 2023
195. Banerji A et al, Long AA, Camargo Jr CA. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. *Allergy Asthma Proc* 2007;28:418–26
196. Wong-Sefdan I, Ale-Ali A, DeMoor PA et al. Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. *J Community Support Oncol* 2014;12:56-64
197. Alvesco® (ciclesonide inhalation aerosol). Drug Product Monograph. Nycomed Canada Inc. 2021 Available from: https://pdf.hres.ca/dpd_pm/00060608.PDF
198. Yang CL, Hick EA, Mitchell P et al. 2021 Canadian Thoracic Society Guideline – A focused update on the management of very mild and mild asthma. *Can J Respir Crit Care Sleep Med* 2021;5:205-245
199. Khongphattbanayothin A, Thomas JLD, Yen L et al. Effects of cisapride on QT interval in children. *J Pediatr* 1998;133:51–56
200. Shulman RJ, Boyle JT, Colletti RB et al. An updated medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. *J Pediatr Gastroenterol Nutr* 2000;31:232-233
201. World Health Organization. Guidelines for the Treatment of Malaria. Geneva: World Health Organization; Nov 30, 2024. Accessed Apr 3, 2025. Available from: <https://www.who.int/publications/i/item/guidelines-for-malaria>
202. Pardiñas AF, Kappel DB, Roberts M, et al. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. *Lancet Psychiatry* 2023;10:209-219
203. BC Centre for Disease Control. Tuberculosis Control Manual. Section 5.0 Treatment of active TB disease. October 2019. Accessed Apr 27, 2022 <http://www.bccdc.ca/health-professionals/clinical-resources/communicable-disease-control-manual/tuberculosis>
204. Taguchi N, Nishikawa T, Inomata S et al. Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide. *Anesth Analg* 1996;82:568-73
205. Ly TT, Maahs DM, Rewers A et al. ISPAD Clinical Practice Consensus Guidelines 2014: Assessment and management of hypoglycemia in children and adolescents with diabetes. *Pediatr Diabetes* 2014;15(Suppl 20):180-92
206. Shannon M, Albers G, Burkart K et al. Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The flumazenil Pediatric Study Group. *J Pediatr* 1997;131:582-6
207. Gharib H, Cook DM, Saenger PH et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Growth Hormone Use in Adults and Children—2003 Update. *Endocr Pract* 2003;9:64-76
208. Wherrett DK, Ho J, Huot C et al. 2018 Clinical Practice Guidelines: Type 1 Diabetes in Children and Adolescents. *Can J Diabetes* 2018;42:S234–S246
209. Kapoor RR, Flanagan SE, James C et al. Hyperinsulinaemic hypoglycemia. *Arch Dis Child* 2009;94:450-7
210. Brendstrup L, Hjelt K, Petersen KE et al. Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infections in children. *Acta Paediatr Scand* 1990;79:1225-34
211. Liu C, Bayer A, Cosgrove SE et al. Clinical Practice Guidelines by the Infectious Disease Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: Executive summary. *Clin Infect Dis* 2011;52:285-92
212. Zeitlin L, Rauch F, Plotkin H et al. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, II, and IV. *Pediatrics* 2003;111:1030-6
213. Ohata Y, Tomita Y, Nakayama Y et al. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. *Drug Metab Pharmacokinet* 2011;26:523-31
214. Strawn JR, Moldauer L, Hahn RD, et al. A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder [published correction appears in *J Child Adolesc Psychopharmacol* 2023;33:200]
215. Zeitler P, Fu J, Tandon N et al. ISPAD Clinical Practice Consensus Guidelines 2014: Type 2 diabetes in the child and adolescent. *Pediatric Diabetes* 2014;15(Suppl 20):26-46
216. Panagiotopoulos C, Riddell MC, Sellers EAC. 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Type 2 diabetes in children and adolescents. *Can J Diabetes* 2013;37:S163-7
217. Ribeiro Barros E, Saraiva GL, Palomo de Oliveira T et al. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. *J Pediatr Endocr Met* 2012;25:485-91

218. Vuorimies I, Toiviainen-Salo S, Hero M et al. Zoledronic acid treatment in children with osteogenesis imperfecta. *Horm Res Paediatr* 2011;75:346-53
219. White NJ, Kim MK, Brousseau DC et al. The anesthetic effectiveness of lidocaine-adrenaline-tetracaine gel on finger laceration. *Pediatr Emerg Care* 2004; 20: 812-5
220. Priestly S, Kelly AM, Chow L et al. Application of topical local anesthetic at triage reduces treatment time for children with lacerations: A randomized controlled trial. *Ann Emerg Med* 2003;42:34-40
221. Hsu DC. Topical anesthetics in children. In: UpToDate. Stack AM (ed) UpToDate. Waltham, MA. (accessed Jan 26, 2015)
222. Singh LK, Nizamie SH, Akhtar S, Prahara SK. Improving tolerability of lithium with a once-daily dosing schedule. *Am J Ther* 2011;18:288-291
223. Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. *Transplantation* 2002;74:966-71
224. Ringsten M, Kredon T, Ebrahim S et al. Diclofenac for acute postoperative pain in children. *Cochrane Database Syst Rev* 2023;12:CD015087
225. Craig JC, Simpson JM, Williams GJ et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med* 2009;361:1848-59
226. Ohata Y, Ohta H, Hashii Y et al. Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective a *Pneumocystis jiroveci* pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation. *Pediatr Blood Cancer* 2009;52:142-4
227. Novartis Pharmaceuticals Corporation. Simulect_(basiliximab) for injection: prescribing information [online]. Available from URL: www.pharma.us.novartis.com/product/pi/pdf/simulect.pdf [Accessed 2025 Jan 14]
228. Bradley JS, Byinton CL, Shah SS, et al. The Management of Community Acquired Pneumonia in Infants and Children Older than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Disease Society and the Infectious Disease Society of America. *Clin Infect Dis* 2011;53:e25-76
229. Cloxacillin for injection. Prescribing Information. SteriMax Inc. Oakville ON. Feb 14, 2019. Accessed Apr 26, 2022. https://pdf.hres.ca/dpd_pm/00049752.PDF
230. Le Saux N. Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than 2 months of age. Canadian Pediatric Society. Oct 19, 2020. Accessed Apr 26, 2022 <https://cps.ca/en/documents/position/management-of-bacterial-meningitis>
231. Acetaminophen injection. Product Monograph. AVIR Pharma Inc. Nov 2018
232. Pringsheim T, Panagiotopoulos C, Davidson J et al. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. *Pediatr Child Health* 2011;16:581-9
233. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al. A new monitoring protocol for clozapine induced myocarditis based on an analysis of 75 cases and 94 controls. *Aust N Z J Psychiatry* 2011;45:458-65
234. American Academy of Child and Adolescent Psychiatry. Practice Parameter for the Assessment and Treatment of Children and Adolescents with Obsessive-Compulsive Disorder. *J Am Acad Child Adolesc Psychiatry* 2012;51:98–113
235. Warren AE, Hamilton RM, Belanger SA et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. *Can J Cardiol* 2009;25:625-30.
236. Greil W, Bauer J, Breit J et al. Single daily dose schedule in lithium long-term treatment: effects on pharmacokinetics and on renal and cardiac functions. *Pharmacopsychiat* 1985;18:106-7
237. Timmer RT, Sands JM. Lithium intoxication. *J Am Soc Nephrol.* 1999;10:666-74
238. Bruni O, Alonso-Alconada D, Besag F et al. Current role of melatonin in pediatric neurology: Clinical recommendations. *Eur J Pediatr Neurol* 2015;19:122-33
239. Emslie GJ, Wagner KD, Kutcher S. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2006;45:709-19
240. Shastri, N. Intravenous Acetaminophen Use in Pediatrics. *Pediatr Emerg Care* 2015;31:444-448
241. European medicines Agency. PRAC recommends restricting use of domperidone. European Medicines Agency 2012: EMA/129231/2014
242. Health Canada. MedEffect Advisory. January 15, 2015. Domperidone – Association with Serious Abnormal Heart Rhythms and Sudden Death (Cardiac arrest) – For Health Professionals <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php>
243. Escudero C, Carr R, Sanatani S. Medical Management of Pediatric arrhythmias. *Curr Treat Options Cardiovasc Med* 2012;14:455-72
244. Escudero C Carr R, Sanatani S. Overview of antiarrhythmic drug therapy for supraventricular tachycardia in children. *Prog Pediatr Cardiol* 2013;35:55-63
245. Workowski KA, Bolan GA. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines. *MMWR Morb Mortal Wkly Rep* 2015;64(RR 3):1-137
246. Ortiz-Alvarez O. Acute Management of croup in the emergency department. *Pediatr Child Health* 2017;22:166-169
247. Canadian Dental Association Position on Use of Fluorides in Caries Prevention. Approved February 2021. http://www.cda-adc.ca/en/about/position_statements/fluoride/
248. Simoes EA, Madhu SA, Muller WJ et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomized controlled trials. *Lancet Child Adolescent Health* 2023;7:180-9
249. Parr JR, Todhunter E, Pennington L et al. Drooling Reduction Intervention randomized trial (DRI): Comparing the Efficacy and Acceptability of Hyoscine Patches and Glycopyrronium Liquid on Drooling in Children With Neurodisability. *Arch Dis Child* 2018;103:371-376
250. BC Guidelines.ca. Guidelines & Protocols Advisory Committee. Iron Deficiency – Diagnosis and Management. 2019
251. Clegg L, Freshwater E, Leach A et al. Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants. *J Clin Pharmacol* 2024;64:555-567
- DynaMedex. Iron Deficiency Anemia in Children. EBSCO Information Services. Accessed February 19, 2025. <https://www.dynamedex.com/condition/iron-deficiency-anemia-in-children>

252. Cray SE, Hall K, Buchanan GR. Intravenous Iron Sucrose for Children with Iron Deficiency Failing to Respond to Oral Iron Therapy. *Pediatr Blood Cancer* 2011;56:615-619
253. Kaplinsky C, Alon US. Magnesium Homeostasis and hypomagnesemia in children with malignancy. *Pediatr Blood Cancer* 2013;60:734-40
254. Peltola H, Paakkonen M. Acute osteomyelitis in children. *N Engl J Med* 2014;370:352-60
255. Bradley JS, Jackson MA. American Academy of Pediatrics, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. *Pediatrics* 2011;128:e1034-45
256. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. *J Clin Oncol* 2012;30:4427-38
257. Perks P, Huynh E, Kaluza K, Boullata JI. Advances in Trace Element Supplementation for Parenteral Nutrition. *Nutrients* 2022 Apr 23;14:1770
258. Office of Dietary Supplements - Vitamin C [Internet]. Nih.gov. 2025 [cited 2025 Mar 12]. Available from: <https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/#en31>
259. Imdad A, Rogner J, Sherwani RN et al. Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years. *Cochrane Database of Systematic Reviews*. 2023 Mar 30:CD009384
260. Sathe M, Patel AS. Update in pediatrics: focus on fat-soluble vitamins. *Nutrition in Clinical Practice* 2010;25:340-346
261. Flynn JT et al. Management of hypertension in the young: role of antihypertensive medications. *J Cardiovasc Pharmacol* 2011;58 (2): 111-120.
262. Le Saux N, Robinson JL; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Management of acute otitis media in children six months of age and older. *Paediatr Child Health* 2016;21:39-44
263. Malani AN. Failure of caspofungin for treatment of *Candida glabrata* candiduria: case report and review of the literature. *Infect Dis Clin Pract* 2010;18:271.
264. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. *Clin Infect Dis* 2007;44:e46-9.
265. Cornely OA et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007; 356: 348-59
266. Patterson TF, Thompson GR, Denning DW et al. Practice Guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Inf Dis* 2016;63:e1-60
267. BC Cancer Magic Mouthwash Launch – Frequently Asked Questions. 01Jun2019. Accessed 31Jul2024 http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Supportive%20Care/SCMMW_FAQ.pdf
268. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. *Antimicrob Agents Chemother* 2009;53(3):958-966.
269. Compounded formulations for symptomatic management of mucositis. Accessed 31Jul2024. Available: <http://www.bccancer.bc.ca/family-oncology-network-site/Documents/SymptomaticManagementofMucositis.pdf>
270. Allen UD. Canadian Paediatric Society. Antifungal agents for the treatment of systemic fungal infections in children. *Paediatr Child Health* 2010;15(9):603-8.
271. Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. *Cochrane Database of Systematic Reviews* 2013, Issue 12. Art. No.: CD005149. DOI: 10.1002/14651858.CD005149.pub4
272. Trotter ED, Chan K, Allain D, et al. Managing an acute asthma exacerbation in children. *Pediatr Child Health*. 2021;26(7):438-439
273. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. *Cochrane Database of Systematic Reviews* 2013, Issue 8. Art. No.: CD000060. DOI: 10.1002/14651858.CD000060.pub2
274. Drysdale SB, Cathie K, Flamein F et al (HARMONIE Study Group). Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. *N Engl J Med* 2023;389:2425-2435
275. Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. *Cochrane Database of Systematic Reviews* 2013, Issue 10. Art. No.: CD009585. DOI: 10.1002/14651858.CD009585.pub2.
276. Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. *Cochrane Database of Systematic Reviews* 2014, Issue 7. Art. No.: CD010283. DOI: 10.1002/14651858.CD010283.pub2.
277. McDonald N, Bara A, McKean MC. Anticholinergic therapy for chronic asthma in children over two years of age. *Cochrane Database of Systematic Reviews* 2003, Issue 3. Art. No.: CD003535. DOI: 10.1002/14651858.CD003535.
278. Koninkx M et al. Management of Status Asthmaticus in Children. *Pediatric Respiratory Reviews* 2013;14:78-85
279. Methylprednisolone High Dose (Pulse) Therapy Protocol. Approved by BCCH PTN Dec 13, 2016.
280. Kidney International Supplements (2012) 2;292-298 Chapter 2: use of iron to treat anemia in CKD The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease
281. Jordan CP et al. Universal ECG changes in pediatric patients undergoing procainamide challenge. *PACE* 2014; 37: 1106-10
282. Plambeck MZ et al. Dexmedetomidine in the pediatrics population: a review. *Minerva Anesthesiol* 2015; 81:320-32
283. Li BL et al. Intranasal dexmedetomidine following failed chloral hydrate sedation in children. *Anaesthesia* 2014; 69: 240-4
284. Ibrahim M. A prospective, randomized, double blinded comparison of intranasal dexmedetomidine vs intranasal ketamine in combination with intravenous midazolam for procedural sedation in school aged children undergoing MRI. *Anesth Essays Res* 2014; 8: 179-86
285. Hitt JM et al. An evaluation of intranasal sufentanil and dexmedetomidine for pediatric dental sedation. *Pharmaceutics* 2014;6:175-84
286. Wang SS, Zhang MZ, Sun Y et al. The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine. *Paediatr Anaesth* 2014;24:275-81

287. Rivkees SA. Pediatric Graves' disease: management in the post-propylthiouracil era. *Int J Pediatr Endocrinol*. 2014;2014(1):10. Epub 2014 Jun 16
288. Caserta MT, O'Leary ST, Munoz FM et al. COMMITTEE ON INFECTIOUS DISEASES; Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics* 2023;152:e2023061803
289. Stabler S. Vitamin B 12 Deficiency. *NEJM* Jan 2013, Vol 368:149-160
290. Roumeliotis N, Dix D, Lipson A. Vitamin B12 deficiency in infants secondary to maternal causes. *Canadian Medical Association Journal* [Internet]. 2012 Jun 18 [cited 2019 Nov 22];184(14):1593–8
291. Diab L, Krebs NF. Vitamin Excess and Deficiency. *Pediatrics in Review*. 2018 Apr;39(4):161–79
292. Cobalamin (vitamin B12) and Folate Deficiency - Province of British Columbia [Internet]. Gov.bc.ca. 2023 [cited 2025 Mar 15]. Available from: <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/vitamin-b12#table5>
293. Firazyr® (icatibant) [Health Canada Product Monograph]. Shire Orphan Therapies, LLC. Lexington, MA. Last revision: November 19, 2015.
294. Li JS et al. Dosing of Clopidogrel for Platelet Inhibition in Infants and young children primary results of the platelet inhibition in Children on Clopidogrel (PICOLO) *Circulation* 2008; 117:553-559
295. Litalien C, et al. Pharmacokinetics of proton pump inhibitors in children. *Clin Pharmacokinet* 2005; 44:441-466
296. Tolia V, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. *JPGN* 2002; 35:S308-312
297. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr* 2018;66:516–54.
298. Sanofi Pasteur. BEYFORTUS® (nirsevimab) Product Monograph [Internet]. Ontario: Sanofi Pasteur Limited; 2024 Mar 14 [cited 2024 Dec 27]. Available from: <https://www.sanofi.com/assets/countries/canada/docs/products/vaccines/beyfortus-en.pdf>
299. Willoughby JL, Bowen CN. Zinc Deficiency and Toxicity in Pediatric Practice. *Curr Opin Pediatr*. 2014 Oct;26(5):579-84
300. Saper RB, Rash R. Zinc: An Essential Micronutrient. *American Family Physician* [Internet]. 2009 May 1;79(9):768–72
301. Fly JH, Eiland LS, Stultz JS. Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children. *Annals of Pharmacotherapy* 2025;59:81-91
302. Lowry CM, Marty FM, Vargis SO et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. *Transpl Infect Dis* 2007; 9: 121-125
303. Saiman L et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2003;290:1749-56.
304. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update. National Kidney Foundation, *Am J Kidney Dis* 2009;53:S11-S104
305. Spino M, Chai RP, Isles AF et al. Cloxacillin absorption and disposition in cystic fibrosis. *J Pediatr* 1984;105(5):829-35
306. Young DC, Zobell JT, Waters CD et al. Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: IV. Colistimethate Sodium. *Pediatr Pulmonol* 2013; 48:1-7.
307. Rosenfeld et al. Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. *JAMA* 2012; 307(21):2269-77
308. Butterworth SA, Lalari V, Dheensaw K. Evaluation of sodium deficits in infants undergoing intestinal surgery. *J Pediatr Surg* 2014;49:736-40
309. Lauer B and Spector N. Vitamins. *Pediatrics in Review*, Aug 2012; 33(8):339-352
310. Tangpricha V et al. An Update on the Screening, Diagnosis, Management, and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation. *J Clin Endocrinol Metab* 2012;97:1-12
311. Willot S et al. Effect of Ursodeoxycholic Acid on Liver Function in Children After Successful Surgery for Biliary Atresia. *Pediatrics* 2008;122:e1236-41
312. El-Shabrawi MHF, et al. Medical Management of Chronic Liver Disease in Children (Part II): focus on the complications of CLD, and CLD trials that require special considerations. *Pediatr Drugs* 2011; 13(6): 371-83.
313. Eaton JE et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Am J Gastroenterol* 2011; 106(9): 1638-45
314. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature. *J Oncol Pharm Pract* 2011.
315. Keeney GE et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. *Pediatrics* 2014; 133: 493-499
316. Kantor PF, Loughheed J, Dancea A et al. Presentation, diagnosis and medical management of heart failure in children: Canadian Cardiovascular Society Guidelines. *Can J Cardiol* 2013;29:1535-52
317. KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. *Arthritis Care Res* 2022;74:521-537
318. Lovell DJ, Ruperto N, Mouy Ret et al. Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. *Arthritis Rheumatol* 2015;67:2759-70
319. Ringsten M, Kredt T, Ebrahim S et al. Diclofenac for acute postoperative pain in children. *Cochrane Database Syst Rev* 2023;12:CD015087
320. Lovell DJ, Brunner HI, Reiff AO et al. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. *RMD Open* 2020;6:e001208

321. Van Rheenen PF, Aloï M, Assa A et al. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. *Journal of Crohn S and Colitis* [Internet]. 2020 Jul 31;15:171–94
322. Djurić Z, Šaranac L, Budić I et al. Therapeutic role of methotrexate in pediatric Crohn's disease. *Bosnian Journal of Basic Medical Sciences* 2018;18:211–6
323. Humphries, R. AST News Update June 2023: New! CLSI M100-Ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas Aeruginosa. *Clinical & Laboratory Standards Institute*, 21 June 2023. Available from: clsi.org/about/blog/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa
324. Epps QJ, Epps KL, Young DC et al. State of the art in cystic fibrosis pharmacology – Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics. *Pediatr Pulmonol* 2020;55:33-57
325. Ilowite N et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. *Clin Rheumatol* 2009; 28:129–137.
326. Ter Haar NM, van Dijkhuizen EHP, Swart JF et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. *Arthritis Rheumatol* 2019;71: 1163-1173
327. Onel KB, Horton DB, Lovell DJ et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. *Arthritis Care Res* 2022;74:521-537
328. Montgomery S, Worswick S. Photosensitizing drug reactions. *Clin Dermatol* 2022 Jan-Feb;40:57-63
329. Kliegman RM, St. Geme J, Joseph W eds. *Nelson Textbook of Pediatrics*. 22nd ed. Philadelphia, PA: Saunders Elsevier; 2025.
330. Wilchanski M, Munck A, Carrion E et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. *Clin Nutr*. 2024;43:413-445
331. Frairia C, Nicolosi M, Shapiro J et al. Sole upfront therapy with beclomethasone and budesonide for upper gastrointestinal acute graft-versus-host disease. *Biol Blood Marrow Transplant* 2020;26:1303-11
332. Hyams JS, Turner D, Cohen SA et al. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study. *Journal of Crohns and Colitis* 2022 Mar 16;16:1243–54
333. Hawkins MJ, Dick AD, Lee RJW, Ramanan AV, Guly CM et al. Managing juvenile idiopathic arthritis-associated uveitis. *Survey Ophthalmology* 2016;61:197-210
334. Cormier, J, Chu, C. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age. *Neuropsychiatric Disease and Treatment* 2013; 9: 295-306
335. Vaisleib, I, Neft, R. Rapid Dosage Titration of Levetiracetam in Children. *Pharmacotherapy* 2008; 28:393-396 (For more rapid titration – cut out day increment)
336. Brophy, G et al. Guidelines for the Evaluation and Management of Status Epilepticus. *Neurocritical Care* 2012;17:3-23
337. Guerrini, R., "Valproate as a Mainstay of Therapy for Pediatric Epilepsy." *Pediatr Drugs*. 2006; 8:113-129
338. Graves NM and Kriel RL, "Rectal Administration of Antiepileptic Drugs in Children," *Pediatr Neurol* 1987;3:321-6
339. Olney, Katie B et al. Daptomycin Dose Optimization in Pediatric *Staphylococcus Aureus* Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation. *J Clin Pharmacol* 2024;64:860-5
340. Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. *BMC Pediatrics* 2022;22
341. Canadian Pediatric Society. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Position Statement. Updated Jan 31, 2018
342. Ralston SL, Lieberthal AS, Meissner HC, Alvenson BK, Baley JE, Gadomski AM, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. *PEDIATRICS*. 2014 Nov 1;134(5):e1474–e1502.
343. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. In: *The Cochrane Collaboration*, editor. *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013 [cited 2015 Mar 10]. Available from: <http://doi.wiley.com/10.1002/14651858.CD006458.pub3>
344. Chen Y-J, Lee W-L, Wang C-M, Chou H-H. Nebulized Hypertonic Saline Treatment Reduces Both Rate and Duration of Hospitalization for Acute Bronchiolitis in Infants: An Updated Meta-analysis. *Pediatr Neonatol*. 2014 Dec;55(6):431–8
345. Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. *BMC Pulm Med*. 2015;15:148
346. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. *Pediatrics*. 2015 Oct;136(4):687–701
347. Lumba-Brown A, Harley J, Lucio S et al. Hypertonic saline as a therapy for pediatric concussive pain. *Pediatr Emerg Care* 2014;30:139-45
348. Mortazaci MM, Romeo AK, Deep A et al. Hypertonic saline for treating raised intracranial pressure: literature review and meta-analysis. *J Neurosurg* 012;116:210- 21
349. Quick Review Summary. Guideline for prevent of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients. Pediatric Oncology Group of Ontario; Toronto, Jan 21, 2021 <http://www.pogo.ca/healthcare/practiceguidelines>
350. British Columbia Cancer Agency Policy Number III-20. Prevention and management of extravasation of chemotherapy. Revised Aug 2021
351. Riggsbee DL, Alali M, Kussin ML. Cidofovir for viral infections in immunocompromised children: Guidance on dosing, efficacy, and a review of the literature. *Ann Pharmacother* 2024;58:286-304
352. Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of Dexrazoxane as a Cardioprotectant in Doxorubicin-Treated Children With High-Risk Acute Lymphoblastic Leukaemia: Long-Term Follow-Up of a Prospective, Randomised, Multicentre Trial. *Lancet Oncol* 2010;11:950-61

353. Daly K, Farrington E. Hypokalemia and hyperkalemia in infants and children: pathophysiology and treatment. *J Ped Health Care* 2013;27:486-96
354. Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. *Arch Dis Child* 2012; 97: 376-380
355. Allen UD, Robinson JL; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Prevention and management of neonatal herpes simplex virus infections. *Paediatr Child Health* 2014;19:201-6
356. James SH, Whitley RJ. Treatment of Herpes simplex virus infections in pediatric patients: current status and future needs. *Clin Pharmacol Ther* 2010; 88:720-24
357. Feigin RD, Cherry J, Demmler-Harrison GJ, Kaplan SL. *Textbook of pediatric infectious diseases*. 7th ed. Philadelphia: Saunders Elsevier; 2014
358. BCCH hematology/oncology bone marrow transplant supportive care guidelines 2012
359. Bomgaars L et al. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. *Pediatr Blood Cancer* 2008;51: 504-8
360. Kimberlin DW et al. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. *Clin Infect Dis* 2010; 50:221
361. Reiss WB et al. Acetazolamide in the treatment of seizures. *Ann Pharmacother* 1996;30:514-9
362. Giraud C et al. In vitro Characterization of Clobazam metabolism by Recombinant Cytochrome P450 Enzymes: Importance of CP2C19. *Drug Metab Dispos* 2004;32: 1279-86
363. Atia O, Shavit-Brunschwig Z, Mould DR et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. *Lancet Gastroenterol Hepatol* 2022;8:31-42
364. McKenzie KC, Hahn CD, Friedman JN. Emergency management of the paediatric patient with convulsive status epilepticus. *Paediatrics & Child Health*. 2021 Jan 21;26:50-7
365. Albani F et al. Immediate (overnight) switching from carbamazepine to oxycarbazepine monotherapy is equivalent to a progressive switch. *Seizure* 2004; 13: 254-263
366. Yeung S, Ensom M. Phenytoin and enteral feedings: Does Evidence support an interaction? *Ann Pharmacother* 2000; 34: 896-904
367. Dellinger RP et al. Surviving sepsis campaign: International guidelines for the management of severe sepsis and septic shock: 22008. *Intensive Care Med* 2008;34:17-60
368. Menon K et al. A systematic review and meta-analysis on the effect of steroids in pediatric shock. *Pediatr Crit Care Med* 2013; 14: 474-80
369. Shulman D et al. Adrenal insufficiency: Still a cause of morbidity and death in childhood. *Pediatrics* 2007; 119: e484-94
370. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:291-322.
371. Mutanen A, Pakarinen MP. Perianal crohn's disease in children and adolescents. *Eur J Pediatr Surg* 2022;30:395-400
372. Sato N et al. Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropin replacement therapy protocols. *Clin Pediatr Endocrinol* 2015;24:37-49.
373. Esposito C et al. Comparison of five different hormonal treatment protocols for children with cryptorchidism. *Scan J Urol Nephrol* 2003;37:247-9
374. Bertelloni S et al. Hormonal treatment for unilateral inguinal testis: Comparison of four different treatments. *Horm Res* 2001;55:236-239
375. BCCH Endocrine test protocols. April 19, 2016
376. Mallick U et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *N Engl J Med* 2012;366:1674-85
377. Francis GL et al. Management Guidelines for children with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2015;25:716-759
378. Hochadel, M. [Editor]. *Mosby's Drug Reference for Health Professions* 5th Edition
379. Azad R et al. Role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus*. 2008;45:36-9
380. Lepore D et al. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. *Ophthalmology*. 2011;118:168-75
381. Dayan JR, Dolinger M, Benkov K et al. Real world experience with ustekinumab in children and young adults at a tertiary care Pediatric Inflammatory Bowel Disease Center. *J Pediatr Gastroenterol Nutrition* 2019;69:61-7
382. Kouksi M, Martinez-Vinson C, Pigneur B et al. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the Pediatric GETAID. *J Pediatr Gastroenterol Nutrition* 2023;76:763-70
383. Charron T et al. Intravenous phosphate in the intensive care unit: More aggressive repletion regimens for moderate and severe hypophosphatemia. *Intensive Care Med* 2003;29:1273-8
384. Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomized controlled trial. *Lancet* 2005;365:573-8
385. Expert Panel Recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology* 2014; 121: 785-796.
386. Nono-Serna LF, Acosta-Reyes J, Veroniki AA et al. Antiemetics in children with acute gastroenteritis: A meta-analysis. *Pediatr* 2020;145:e20193260
387. Patel P, Robinson PD, Thackray J, Flank K, Holdsworth MT et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. *Pediatr Blood Cancer* 2017;64:e26542
388. Galardy PJ et al. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: A Children's Oncology Group Report. *BMJ* 2013; 163: 365-372
389. Friedrichsdorf SJ et al. The management of pain in children with life-limiting illnesses. *Pediatr Clin N Am* 2007; 54: 645-72
390. Hershey AD et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. *Headache* 2000; 40: 539-49

391. Wasiewski WW. Preventative therapy in pediatric migraine. *J Child Neurol* 2001;16:71-8
392. Bonfert M et al. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. *Neuropediatrics* 2013;44:3-19
393. McGlone R et al. A comparison of intramuscular ketamine with high dose intramuscular midazolam with and without intranasal flumazenil in children before suturing. *Emerg Med J* 2001; 18:34-8
394. Health Canada Information Update. Health Canada's review recommends codeine only be used in patients aged 12 and over. June 6, 2013. Accessed at: <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/33915a-eng.php>
395. Cohen S, Rolandsdotter H, Kolho KL et al. Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN. *Pediatr Drugs* 2024;26:609–17
396. Health Canada Information Update. New safety measures for prescription codeine and hydrocodone to further restrict use in children and adolescents. July 28, 2016. Accessed at <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59584a-eng.php>
397. FDA Drug Safety Communication. Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. August 15, 2012. Accessed at: <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM339116.pdf>
398. Sheehy KA et al. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. *BMC Pediatr* 2015;15:198
399. Pestieau SR et al. Prolonged perioperative infusion of low-dose ketamine does not alter opioid use after pediatric scoliosis surgery. *Pediatr Anesthesia* 2014;24:582-90
400. Holh CM et al. Methotrimeprazine for the management of end-of-life symptoms in infants and children. *J Palliative Care* 2013;29:178-95
401. Topjian AA et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2020; 142(suppl 2); S469-S523
402. Miller JL, Hagemann TM. Use of pure opioids antagonists for management of opioid-induced pruritis. *Am J Health Syst Pharm* 2011; 68(15): 1419-1425
403. Maxwell LG et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. *Anesth Anal* 2005; 100: 953-8
404. Ganesh A et al. Pathophysiology and management of opioid-induced pruritus. *Drugs* 2007; 67(16): 2323-33
405. Lindor et al. High Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis. *Hepatology* 2009;50:808-814
406. Kasap B. Sirolimus in pediatric renal transplantation. *Pediatr Transplantation* 2011; 15: 673-85.
407. Pape L et al. mTOR inhibitors in pediatric kidney transplantation. *Pediatr Nephrol* 2014; 29:1119-1129
408. Ganschow R et al. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. *Pediatr Transplantation* 2013;17:694-706
409. Kang HJ et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized, double-blind, phase 3 trial. *Lancet Oncol* 2015;16:385-94
410. Patel P et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. *Pediatr Blood Cancer* 2022;69:e30001
411. Friedrichsdorf SJ and Nugent AP. Management of Neuropathic Pain in Children with Cancer. *Current Opinion in Supportive and Palliative Care* 2013:131-8
412. Lipidrescue.org
413. SOGC Clinical Practice Guideline. Abnormal Uterine Bleeding Pre-Menopausal Women. *J Obstet Gynaecol Can* 2018;40:e391–e415
414. Burns J, Davenport M. Adjuvant treatments for biliary atresia. *Translational Pediatrics* 2020 Jun 1;9:253–65
415. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. *J Pediatr Pharmacol Ther.* 2020;25:175-191
416. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. *Curr Med Res Opin* 2010;26:2047-55
417. Ortiz de la Rosa JS, Ladino LD, Rodriguez PJ, Rueda MC, Polania JP, Castaneda AC. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. *Seizure.* 2018;56:34-40
418. Gross S et al. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. *Eur J Pediatr Neurol* 2014;18:55-59
419. Miskin C et al. Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy. *J Child Neurol* 2016; 31(7): 925-929
420. Sant' Anna AM, et al. Use of cyproheptadine in young children with difficulties and poor growth in a pediatric feeding program. *J Pediatr Gastroenterol Nutr* 2014; 59: 674-678
421. Chavhan GB et al. MR enterography in children: Principles, technique, and clinical applications. *Indian J Radiol Imaging* 2013 Apr-Jun; 23:173–178
422. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. *Drugs* 2007;67:1343-57
423. Tabbers MM, Di Lorenzo C, Berger MY et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol Nutr* 2014;58:258-274
424. El-Shabrawi MH et al. Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. *Paediatr Drugs* 2011;13:371-83
425. Blei AT et al. Hepatic Encephalopathy. *Am J Gastroenterol* 2001;96:1968-76
426. Li ST, Grossman DC, and Cummings P. Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-analysis. *PLoS Med*, 2007;4:e98

427. Kaplan MA et al. A multicenter randomized controlled trial of liquid loperamide product versus placebo in the treatment of acute diarrhea in children. *Clin Pediatr (Phila)* 1999;38:579-591
428. Sandhu BK, Tripp JH, Milla PJ, et al, "Loperamide in Severe Protracted Diarrhoea," *Arch Dis Child* 1983;58:39-43
429. Rufo PA et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. *J Pediatr Gastroenterol Nutr.* 2012;55:93-108
430. Health Canada. MedEffect Advisory. January 5, 2015. Metoclopramide – Abnormal involuntary movements (Extrapyramidal symptoms) in children. <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43167a-eng.php>
431. Koseoglu V, Kurekci AE, Sorici U. Comparison of the efficacy and side effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: A prospective randomized study. *Eur J Pediatr* 1998;157:806-10
432. Vanderplas Y et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr* 2009;49:498-547.
433. Blackmer AB et al. Constipation in the Pediatric Patient: An Overview and Pharmacologic Considerations. *J Pediatr Health Care.* 2010; 24: 385-399
434. Tammara BK et al. Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month Through <6 Years With Gastro-oesophageal Reflux Disease. *Clin Pharmacokinet* 2011;50:541-50
435. Ward RM et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with GERD. *J Clin Pharmacol* 2011;51:876-887
436. Pettersen G et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. *Br J Clin Pharmacol* 2009;67:216-227
437. Tuggle DW et al. The safety and cost-effectiveness of polyethylene glycol electrolyte solution bowel preparation in infants and children. *J Pediatr Surg* 1987;22:513-5
438. Sondheimer JM et al. Safety, efficacy and tolerance of intestinal lavage in pediatric patients undergoing diagnostic colonoscopy. *J Pediatr* 1991;119:148-52
439. Turner et al. Pico-Salax versus polyethylene glycol for bowel cleanout before colonoscopy in children: a randomized controlled trial. *Endoscopy* 2009;41:1038-45
440. De Marco G, Sordino D, Bruzzese E et al. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. *Alimentary Pharmacology & Therapeutics* 2006;24:387–94
441. Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with Alagille Syndrome. *Journal of Pediatric Gastroenterology and Nutrition* 2013;57:149–54
442. Reveiz L, Guerrero-Lozano R, Camacho A et al. Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: A systematic review. *Pediatr Crit Care Med* 2009;11:124–32
443. Thorburn K, Samuel M, Smith EA, Baines P. Aluminum accumulation in critically ill children on sucralfate therapy. *Pediatr Crit Care Med* 2001;2:247–9
444. Ellwood J, Draper-Rodi J, Carnes D. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines. *BMJ Open* 2020;10(2):e035405
445. European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson's Disease. *J Hepatology* 2025;82:690-728
446. Laborda TJ, Jensen MK, Kavan M, Deneau M. Treatment of primary sclerosing cholangitis in children. *World Journal of Hepatology* 2019;11:19–36
447. EASL Clinical Practice Guidelines: Autoimmune hepatitis. *Journal of Hepatology* 2015;63:971–1004
448. James, AH et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. *Eur J Obstet Gynecol Reprod Biol* 2011;158:124-34
449. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017; 35 3240-3261
450. Buchen S et al. Carboxypeptidase G₂ rescue in patients with methotrexate intoxication and renal failure. *Br J Cancer* 2005;92:480-487
451. Bradley AM et al. Successful use of intrathecal carboxypeptidase G₂ for intrathecal methotrexate overdose: A clinical case study and review of the literature. *Clin Lymphoma* 2013;13:166-70
452. Voraxaze product monograph https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/1253271bl.pdf
453. Tranexamic Acid (TXA) in the Emergency Department : Emergency Care BC. Last Rev Feb 3, 2024. Accessed Jan 5, 2025. <https://emergencycarebc.ca>
454. Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. *Cochrane Database Syst Rev* 2009;3:CD001000.
455. Sharar SR, Bratton SL, Carrougher GJ et al. Comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. *J Burn Care Rehabil* 1998;19:516-21
456. Sharar SR, Carrougher GJ, Selzer K et al. Comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. *J Burn Care Rehabil* 2002;23:27-31
457. Mahar PJ, Rana JA, Kennedy CS et al. Randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. *Pediatr Emerg Care* 2007;23:544-8
458. Wheeler M, Birmingham PK, Dsida RM et al. Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. *Pediatric Anaesthesia* 2002;12:594-9
459. Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. *Palliative Medicine* 2001;15:323-8
460. Escudero C et al. The medical management of arrhythmias. *Current Treatment Options in Cardiovascular Medicine* 2012;14:455-72
461. Escudero C et al. Overview of antiarrhythmic drug therapy for supraventricular tachycardia in children. *Progress in Pediatric Cardiology* 2013;35:55-63

462. Patel NH et al. Evaluation and management of pediatric hypertensive crises: hypertensive urgency and hypertensive emergencies. *Open Access Emerg Med* 2012;4:85-92
463. Delgado MR et al. Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). *Neurology* 2010;74:336-343
464. Klein EJ, Brown JC, Kobayashi A et al. A randomized clinical trial comparing oral, aerosolized intranasal, and aerosolized buccal midazolam. *Ann Emerg Med* 2011;58:323-9
465. Jazz Pharmaceuticals Ireland Limited. Defitelio™ Product Monograph. 10 July 2017
466. Richardson PG, Riches ML, Kernana NA et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. *Blood* 2016;127:1656-65
467. Richardson PG et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive/sinusoidal obstruction syndrome improves day +100 survival following haematopoietic stem cell transplantation. *Br J Haematol* 2017;178:112-118
468. Zulanga M. Chylothorax after surgery for congenital heart disease. *Current Opinion in Pediatrics* 2012;24:291-4
469. Demirkilek H, Shah P, Bhushan Arya V et al. Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy. *J Clin Endocrinol Metab* 2014;99:3660-7
470. Eroglu Y, Emerick KM, Whitingon PF et al. Octreotide therapy for control of acute gastrointestinal bleeding in children. *J Pediatr Gastroenterol Nutr* 2004;38:41-7
471. Wise-Faberowski L et al. Perioperative management of diabetes insipidus in children. *J Neurosurg Anesthesiol* 2004;16:220-3
472. Horimoto Y, Tomie H, Hanzawa K et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. *Can J Anesthesia* 1991;38:441-4
473. Lewis DW, Fontana C, Mehallick LK et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. *Developmental medicine and child neurology* 1994;36:484-6
474. Zelenitsky S, Ariano R, Harding G, Forrest A. Evaluating ciprofloxacin dosing for *Pseudomonas aeruginosa* infection by using clinical outcome-based Monte Carlo simulations. *Antimicrob Agents Chemother* 2005;10:4009-14
475. Crash-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2): a randomized placebo-controlled trial. *Lancet* 2010;376:23-32
476. Eckert MJ, Wetin TM, Tyner SD et al. Tranexamic acid administration to pediatric trauma patients in the combat setting: The pediatric trauma and tranexamic acid study (PED-TRAX). *J Trauma Acute Care Surg* 2014;77:852-8
477. Faraoni D, Goobie SM. The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: A systematic review of the literature. *Anesth Analg* 2014;118:628-36
478. Skeens M et al. Twice daily I.V. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. *Bone Marrow Transplant* 2012;47:1415-8
479. Ammar A, Mahmoud K, Kasemy Z. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. *Acta Anaesthesiologica Scandinavica* 2017;61:374-380
480. Won YJ, Lim BG, Lee DK, Kim H, Kong H, Lee IO. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients A systematic review and meta-analysis. *Medicine* 2016;95
481. Aksoy B, Baran M, Appak YC et al. Efficiency of azathioprine monotherapy for maintenance treatment of autoimmune hepatitis in children. *Eur J Gastroenterol Hepatol* 2020;34:92-7
482. Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. *Pediatr Crit Care Med* 2022;23:e74-110
483. Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. *Cephalalgia* 2014;34:365-75
484. Sheiko MA, Sundaram SS, Capocelli KE et al. Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites. *J Pediatr Gastroenterol Nutr* 2017;65:80-5
485. BC Transplant. MEDICATION GUIDELINES FOR SOLID ORGAN TRANSPLANTS [Internet]. Clinical Guidelines for Transplant Medications. 2021
486. Rowan-Legg A. Managing functional constipation in children. *Paediatr Child Health* 2011;16:661-5
487. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. *J Clin Pharmacol* 2002;42:1219-27
488. Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database Syst Rev* 2017;7:CD009377
489. Meena JP, Gupta AK, Jat KR et al. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in children: a systematic review and meta-analysis of randomized controlled trials. *J Pediatr Hematol Oncol* 2023;45:361-9
490. Radhakrishnan V, Pai V, Rajaraman S et al. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial. *Pediatr Blood Cancer* 2020;67:e28532
491. Luc QN, Querubin J. Clinical Management of Dystonia in Childhood. *Paediatr Drugs*. 2017 Oct;19:447-461
492. Goyal V, Laisram N, Wadhwa RK, Kothari SY. Prospective randomized study of oral diazepam and baclofen on spasticity in cerebral palsy. *J Clin Diagn Res*. 2016;10:RC01-RC5
493. Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. *J Child Neurol*. 2006;21:1090-1092
494. Diantini A, Alfaqeeh M, Permatasari LI et al. Clinical Toxicology of OTC Cough and Cold Pediatric Medications: A Narrative Review. *Pediatric Health Med Ther* 2024;15:243-255
495. Mulhem E, Khondoker F, Kandiah S. Constipation in children and Adolescents: Evaluation and treatment. *Am Fam Physician* 2022;105:469-78
496. Harrison ME, Norris ML, Robinson A et al. Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review. *Appetite* 2019;137:62-72

497. Badihian N, Saneian H, Badihian S, Yaghini O. Prophylactic therapy of cyclic vomiting syndrome in children: comparison of amitriptyline and cyproheptadine: a randomized clinical trial. *Am J Gastroenterol* 2017;113:135–40
498. Berlucchi M, Valetti L, Parrinello G, et al, "Long-Term Follow-Up of Children Undergoing Topical Intranasal Steroid Therapy For Adenoidal Hypertrophy," *Int J Pediatr Otorhinolaryngol* 2008;72:1171-5
499. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. *Ital J Pediatr* 2019;45:101
500. Pathirana S, Jayawardena S, Meeves S, Thompson GA. Brompheniramine and Chlorpheniramine Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years. *J Clin Pharmacol* 2018;58:494-503
501. Parisi GF et al. Cetirizine use in childhood: an update of a friendly 30-year drug. *Clin Mol Allergy* 2020;18:2
502. Kapur S, Zipursky RB, Jones C et al. Cyproheptadine: a potent in vivo serotonin antagonist. *Am J psychiatry* 1997;154:884
503. Dahl SG. Pharmacokinetics of methotrimprazine after single and multiple doses. *Clin Pharmacol Ther* 1976;19:435-42
504. US Food & Drug Administration. (Trade name: Orenzia) [Internet]. Maryland: US Food & Drug Administration; 2024 [Jan 2025]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125118s255lbl.pdf
505. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1 and 2: ambulatory care-evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr.* 2018;67(2):257-310
506. NICE. Constipation in children and young people: diagnosis and management [Internet]. 2010 May. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554924/pdf/Bookshelf_NBK554924.pdf
507. De Zoeten EF, Pasternak BA, Mattei P et al. Diagnosis and treatment of perianal Crohns disease. *J Pediatr Gastroenterol Nutr* 2013;57:401–12
508. Hendler SA, Cohen BL, Colombel JF et al. High-Dose Infliximab therapy in Crohn's Disease: clinical experience, safety, and efficacy. *Journal of Crohns and Colitis* 2014;9:266–75
509. Choy MC, Suen CDFLW, Con D et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2024;9:981–96
510. Product Monograph: ACTEMRA tocilizumab solution for injection. Hoffmann-La Roche Limited. Mississauga, Ontario 2021
511. Maccora I, Simonini G, Guly CM, Ramanan AV. Management of JIA associated uveitis. *Best Pract Res Clin Rheumatol* 2024 Sep;38(3):101979
512. Elbe D, Macbride A, Reddy D. Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. *J Can Acad Child Adolesc Psychiatry* 2010;19:303-14
513. Elbe D, Reddy D. Focus on Guanfacine Extended-release: A Review of its Use in Child and Adolescent Psychiatry. *J Can Acad Child Adolesc Psychiatry* 2014;23:48-60
514. Theurich S, Fischmann H, Chakupurakal G et al. Anti-thymocyte globulins for post-transplant graft-versus host disease prophylaxis- A systematic review and meta-analysis. *Crit Rev Oncol Hematol* 2013;88:178-86
515. Patel P, Leeder JS, Piquette-Miller M et al. Aprepitant and fosaprepitant drug interactions: a systematic review. *Br J Clin Pharmacol* 2017;83:2148-62
516. Gouin S, Vo TT, Roy M et al. Oral dimenhydrinate versus placebo in children with gastroenteritis: a randomized controlled trial. *Pediatric* 2012;129:1050-5
517. Kranke P, Morin M, Roewer N et al. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. *Acta Scand* 2002;46:238-44
518. Sung L, Nathan PC, Lange B et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. *J Clin Oncol* 2004;22:3350-6
519. Ramsey LB, Balis FM, O'Brien M et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. *Oncologist* 2018;23:52-61
520. Polito S, MacDonal R, Romanick M et al. Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review. *Pediatr Blood Cancer* 2018;65:e27374
521. Khalil SN, Roth AG, Cohen IT et al. Double-blind comparison of intravenous ondansetron and placebo for preventing post-operative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia. *Anesth Analg* 2005;101:356-61
522. Gan T, Belani K, Bergese S et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg* 2020;131:411-48
523. Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy –induced nausea and vomiting in children with cancer. *Pediatr Blood Cancer* 2016;63:1144-51
524. Kovacs G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapy induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. *Lancet Oncol.* 2016;17(3):332–344.
525. Wang J, Mehrotra N, Kim I et al. Exposure-response of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients. *J Pediatr Gastroenterol Nutr* 2016;63:412-6
526. Kruizinga MD, Bresters D, Smiers FJ et al. The use of intravenous pentamidine for the prophylaxis of *Pneumocystis pneumonia* in pediatric patients. *Pediatr Blood Cancer* 2017;64:e26453
527. Quinn M, Fannin JT, Sciasci J et al. Pentamidine for prophylaxis against *Pneumocystis jirovecii pneumonia* in pediatric oncology patient receiving immunosuppressive chemotherapy. *Antimicrobial Agents Chemother* 2018;62:e00173-18
528. Children's Oncology Group Leukemia Guidelines
529. Children's Oncology Group Long-Term Follow-up Guidelines

530. Sun et al. Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes. *Medicine (Baltimore)* 2016;95:e5228
531. De Giorgi U et al. High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patient with high-risk stage II-IIIa breast cancer. *Bone Marrow Transplant* 2003;32:251-5
532. Vachhani P et al. Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia. *Leuk Res Rep.* 2017; 7: 36–39
533. Brar et al. Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism. *J Clin Endocrinol Metab.* 2020 Dec 1;105(12)
534. Kuskonmaz B, Yalcin S, Kucukbayrak O et al. The effect of glutamine supplementation on hematopoietic stem cell transplant outcome in children: A case–control study. *Pediatr Transplantation* 2008; 12: 47–51
535. Ward E, Smith M, Henderson M et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. *Eur J Clin Nutr* 2009;63:134-40
536. Tambralli A, Beukelman T, Weiser P et al. High doses of infliximab in the management of juvenile idiopathic arthritis. *J Rheumatol* 2013;40:1749-55
537. Montagnese S, Rautou PE, Romero-Gómez M et al. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. *J Hepatol* 2022;77:807–24
538. Soman T, Rafay MF, Hune S et al. The risks and safety of clopidogrel in pediatric arterial ischemic stroke. *Stroke* 2006;37:1120-2
539. Brittenham GM. Iron-chelating therapy for transfusional iron overload. *N Engl J Med* 2011;364:146-56
540. Huang JY, Monagle P, Massicotte PM. Antithrombotic therapies in children on durable Ventricular Assist Devices: A literature review. *Thrombosis Research* 2018;172:194-203
541. Mitchell JP, Nagel MW. Particle Size Analysis of Aerosols from Medicinal Inhalers. *Kona Powder and Particle Journal.* Volume 22. Sep 21, 2004.
542. Rameshkumar R et al. Randomized clinical trial of 20% mannitol versus hypertonic saline in children with raised intracranial pressure due to acute CNS infection. *Pediatr Crit Care Med* 2020;21:1071-80
543. Kumari N et al. Comparative assessment of hypertonic saline versus mannitol in the treatment of raised intracranial tension in children. *EJMCM* 2020;7:3968-74
544. Shi J et al. Hypertonic saline and mannitol in patients with traumatic brain injury. A systematic and meta-analysis. *Medicine (Baltimore)* 2020;99:e21655
545. Oskoui M. et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents. *Neurology* 2019;93:489-499
546. Wang G; Tan T; Liu Y; Hong P. Drugs for acute attack of pediatric migraine: A network meta-analysis of randomized controlled trials. *Clinical Neurology and Neurosurgery* 2020;195:105853
547. Afshar M. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. *Pediatr Neurol* 2014;50:625-9
548. Athale U, Hijjiya N, Patterson BC et al. Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children’s Oncology Group CML Working Group. *Pediatr Blood Cancer* 2019;66:e27827
549. Children’s Oncology Group. A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid AAML1331
550. National Heart, Lung, and Blood Institute (NHLBI). Evidence-based management of sickle cell disease: expert panel report, 2014. Bethesda, MD: National Institutes of Health; 2014. <http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines>. Accessed August 13, 2021.
551. TauroSept® Product Monograph (Geistlich Pharma)
552. Chu HP, Brind J, Tomar R, Hill S. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine lock. *J Pediatr Gastroenterol Nutr* 2012;55(4):403-7.
553. Hulshof EC, Hanff LM, Olieman J et al. Taurolidine in pediatric home parenteral nutrition patients. *Pediatr Infect Dis J* 2017;36(2):233-5.
554. Trottier et al. Canadian Pediatric Society Position Statement: Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures. *Paediatr Child Health* 2019 24(8):509-521.
555. AAP COMMITTEE ON FETUS AND NEWBORN and SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE. Prevention and Management of Procedural Pain in the Neonate: An Update. *Pediatrics.* 2016;137(2):e20154271
556. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. *Epilepsy Curr.* 2016;16(1):48-61.
557. McKenzie KC, Hahn CD, Friedman JN. Canadian Pediatric Society position statement: Emergency management of the paediatric patient with convulsive status epilepticus. *Paediatr Child Health* 2021;26(1):50-57
558. Kumar A, Reljic T, Hamadani M et al. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. *Bone Marrow Transplant* 2019;54:1094-1106
559. Dhiman RK, Thumburu KK, Verma N et al. Comparative Efficacy of Treatment options for minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. *Clinical Gastroenterology and Hepatology* 2019;18:800-812
560. BC Children’s Hospital. Division of Hematology, Oncology, and Blood and Marrow Transplant. BMT Supportive Care Guidelines. Nov 12, 2019.
561. BC Transplant Clinical Guidelines for Transplant Medications. 2021. <http://www.transplant.bc.ca/Documents/Health%20Professionals/Clinical%20guidelines/Clinical%20Guidelines%20for%20Transplant%20Medications.pdf>
562. Vukadinović D, Scholz SS, Messerli FH, et al. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. *J Hypertens.* 2019;37(10):2093–2103.

563. Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. *Br J Clin Pharmacol*. 2000;50(5):455-463.
564. Josefsson M, Ahlner J. Amlodipine and grapefruit juice. *Br J Clin Pharmacol*. 2002;53(4):405
565. Baracco, R. A Practical Guide to the Management of Severe Hypertension in Children. *Pediatr Drugs* 2020;22, 13–20
566. Suresh S, et al. The European Society of Regional Anaesthesia and Pain Therapy/American Society of Regional Anesthesia and Pain Medicine recommendations on local anesthetics and adjuvants dosage in pediatric regional anesthesia. *Reg Anesth Pain Med* 2018;43:211-6.
567. Suresh S, Polaner D, Cote CJ. Regional anesthesia. In: Cote CJ, Lerman JB, Anderson BJ, eds. *Pract Anesth Infants Child*. 6th ed. Philadelphia, PA: Elsevier, Inc; 2019:941-87.
568. Tsui B, Boretsky K, Berde C. Maximum recommended dosage of ropivacaine and bupivacaine for pediatric regional anesthesia. *Reg Anesth and Pain Med* 2018;43(8):895-6.
569. Bosenberg AT, Thomas J, Lopez T, Huledal G, Jeppsson L, Larsson LE. Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 or 3 mg/kg in children. *Acta Anaesthesiol Scand*. 2001;45:1276-80.
570. NYSORA – Regional Anesthesia in Pediatric Patients: General Considerations. Available: <https://www.nysora.com/foundations-of-regional-anesthesia/sub-specialties/pediatric-anesthesia/regional-anesthesia-pediatric-patients-general-considerations/>
571. Berde CB, Strichartz GR. Local anesthetics. In: Miller RD, editor. *Miller's Anesthesia*. Eighth edition. Philadelphia: Elsevier; 2015.
572. Mina R et al. Consensus treatment plans for induction therapy of newly-diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. *Arthritis Care Res*. 2012 March; 64(3): 375–383.
573. EUVAS protocol: De Groot K et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody– associated vasculitis: a randomized trial. *Ann Intern Med*. 2009;150: 670-680
574. <http://www.bcrenal.ca/resource-gallery/Documents/Supporting%20Evidence%20Document-Cyclophosphamide%20Protocol%20for%20MCD%20and%20FSGS.pdf>
575. Reddy S, Kamath N. Clinical approach to renal tubular acidosis in children. *Karnataka Pediatric Journal*. 2021 Jan 25;35(2):88-94
576. Bupivacaine Local Anesthetic, solution [prescribing information]. Kirkland, Quebec: Pfizer Canada ULC; February 2019
577. Chen Z, Lin M, Huang Z et al. Efficacy of chloral hydrate oral solution for sedation in pediatrics: a systematic review and meta-analysis. *Drug Design, Development and Therapy* 2019;13:2643-53
578. Fong CY, Lim WK, Li L et al. Chloral hydrate as a sedating agent for neurodiagnostic procedures in children. *Cochrane Database of Systematic Reviews* 2021, Issue 8. Art No: CH011786
579. Thigpen JC et al. Opioids: a review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. *Eur J Drug Metab Pharmacokinet* 2019; 44(5): 591-609
580. Hegenbarth MA, Committee on Drugs. Preparing for pediatric emergencies: Drugs to consider. *Pediatrics* 2008;121(2):433-43.
581. RxFiles. PPI DEPRESCRIBING Approaches for stopping or dose reduction of PPIs in those who may not need lifelong treatment [Internet]. 2015 Mar. Available from: <https://www.rxfiles.ca/rxfiles/uploads/documents/PPI-deprescribing-newsletter.pdf>
582. McNichol ED et al. Ketorolac for postoperative pain in children. *Cochrane Database Syst Rev* 2018;7:CD012294
583. Miller JL, Hagemann TM. Use of pure opioid antagonists for management of opioid-induced pruritis. *Am J Health Syst Pharm* 2011;68:1419-1425
584. Thompson JS, Rochling FA, Weseman RA, Mercer DF. Current management of short bowel syndrome. *Current Problems in Surgery* 2012;49:52–115
585. Pall H, Zacur GM, Kramer RE et al. Bowel preparation for pediatric colonoscopy. *Journal of Pediatric Gastroenterology and Nutrition* 2014;59:409–16
586. Matsui M et al. Reversibility of Rocuronium-Induced Deep Neuromuscular Block with Sugammadex in Infants and Children—A Randomized Stud. *Biol Pharm Bull* 2019;42:1637-1640.
587. Ferric Derisomaltose (iron isomaltoside) Product Monograph. Pfizer Canada. Kirkland, Canada. Sep 16, 2021 https://pdf.hres.ca/dpd_pm/00062976.PDF
588. Lane, Roni D, et al. Amiodarone for the Emergency Care of Children, *Pediatric Emergency Care*: May 2010 - Volume 26 - Issue 5 – p382-389 doi: 10.1097/PEC.0b013e3181ddd2d6
589. January CT, Wann S, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. *Circulation* 2014;130:e199-267
590. Cunningham T, Uzun O, Morris R, Franciosi S, Wong A, Jeremiasen I, Sherwin E, Sanatani S. The Safety and Effectiveness of Flecainide in Children in the Current Era. *Pediatr Cardiol*. 2017 Dec;38(8):1633-1638. doi: 10.1007/s00246-017-1707-5. Epub 2017 Aug 24. PMID: 28840327
591. Sheno, Rohit P., et al. "Drugs Used to Treat Pediatric Emergencies." *American Academy of Pediatrics, American Academy of Pediatrics*, 1 Jan. 2020 pediatrics.aappublications.org/content/145/1/e20193450
592. Singh M, McKenzie K, Hudak ML, Gehi AK, and Ferns SJ (2021). Electrophysiological effects and clinical utility of propafenone in children. *Cardiology in the Young*, page 1 of 5. doi: 10.1017/S1047951121002857
593. Waldman AR, Ahluwalia J, Udoff J, et al. Atopic dermatitis. *Pediatr Rev* 2018;39(4):180-191.
594. Yang EJ, Sekhon S, Sanchez IM, et al. Recent developments in atopic dermatitis. *Pediatrics* 2018;142(4): e20181102
595. Tollefson MM, Bruckner AL. Atopic dermatitis: skin-directed management. *Pediatrics* 2014;134(6):e1735-e1744
596. Weinstein M, Barber K, Bergman J, et al. (2018). Atopic dermatitis: a practical guide to management. Retrieved from https://eczemahelp.ca/wp-content/uploads/2019/03/ESC_AD_Practical-Guide-to-Management-for-HCP_2019.pdf
597. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics* 2013;131:S163-S186
598. Ashton R, Weinstein M. Acne vulgaris in the pediatric patient. *Pediatr Rev* 2019;40(11):577-589.
599. Cummings C, Finlay JC, MacDonald NE. Head lice infestations: a clinical update (Canadian Paediatric Society Practice Point). *Paediatr Child Health* 2018;23(1):e18-24

600. Banerji A. Scabies (Canadian Paediatric Society Position Statement). *Paediatr Child Health* 2015;20(7):395-8
601. Trotter ED, Dore-Bergeron MJ, Chauvin-Kimoff L, et al. Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures (Canadian Pediatric Society Position Statement). *Paediatr Child Health* 2019;24(8):509-21
602. Tillman EM, Smetana KS, Bantu L et al. Pharmacologic Treatment for Pediatric Gastroparesis: A Review of the Literature. *J Pediatr Pharmacol Ther* 2016;21:120–32
603. Canadian Pediatric Society (2019 June). Antifungal agents for common outpatient paediatric infections. Retrieved from <https://www.cps.ca/documents/position/antifungal-agents-common-infections>
604. BC Centre for Disease Control (2020). Non-certified practice decision support tool: vulvovaginal candidiasis (VVC). Retrieved from <http://www.bccdc.ca/resource-gallery/Documents/Communicable-Disease-Manual/Chapter%20-%20STI/Non-certified%20VVC%20DST.pdf>
605. Van Schalkwyk J, Yudin MH. SOGC clinical practice guideline – vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. *J Obstet Gynaecol Can* 2015;37(3):266-274.
606. Patel P, Olteanu A, Cabral S et al. Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review. *Pediatr Blood Cancer* 2020;67:e28716
607. Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson DW, Klassen TP. Glucocorticoids for croup in children. *Cochrane Database Syst Rev*. 2018 Aug 22;8(8)
608. Le Saux N, Robinson JL; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Uncomplicated pneumonia in healthy Canadian children and youth: Practice points for management. Oct 31, 2018. <https://cps.ca/documents/position/pneumonia-management-children-youth> [accessed Apr 11, 2022]
609. Tompkins MG and Pettit R. Beyond the Guidelines: Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. *Ann Pharmacother*. 2022;56(2):181-192
610. Floto RA, Olivier KN, Saiman L, et al. US CFF and ECFS consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. *Thorax* 2016;71:i1–i22
611. Mas E, Borrelli O, Broekaert I et al. Drugs in focus. *J Pediatr GastroenterolNutrit* 2021;74:1–6
612. Lehrnbecher T, Fisher BT, Phillips B et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. *J Clin Oncol* 2020;38
613. Brownell JN et al. Growth and Nutrition in Cystic Fibrosis. *Semin Respir Crit Care Med* 2019;40:775-791
614. Le Saux, N. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Diagnosis and management of acute osteoarticular infections in children. *Paediatr Child Health* 2018;23:336-43
615. Woods CR, Bradley JS, Chatterjee A et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. *J Pediatr Infect Dis Soc* 2021. Accessed Apr 26, 2022 <https://www.idsociety.org/globalassets/idsa/practice-guidelines/piab027.pdf>
616. Zobell JT, Waters CD, Young DC et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins. *Pediatr Pulmonol* 2013;48:107-22.
617. Shoji K, Bradley JS, Reed MD et al. Population pharmacokinetic assessment and pharmacodynamics implications of pediatric cefepime dosing for susceptible-dose dependent organisms. *Antimicrobial Agents and Chemotherapy* 2016;60:2150-6
618. Inaba H, Gaur AH, Cao X et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. *Cancer* 2014;120:1985-92
619. DeRonde KJ, Giroto JE, Nicolau DP. Management of pediatric acute hematogenous osteomyelitis part II: A focus on methicillin-resistant *Staphylococcus aureus*, current and emerging therapies. *Pharmacotherapy* 2018;38:1021-37
620. Erythromycin ophthalmic ointment. Prescribing Information. Steri-Med Pharma Inc. Upton, Quebec. May 3, 2021. Accessed Apr 27, 2022 https://pdf.hres.ca/dpd_pm/00061356.PDF
621. Ljungman P, de la Camara R, Robin C, et al, on behalf of the 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). *Lancet Infect Dis* 2019; published online May 29, 2019 [http://dx.doi.org/10.1016/S1473-3099\(19\)30107-0](http://dx.doi.org/10.1016/S1473-3099(19)30107-0)
622. Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. *Blood* 2002;99:1159-64
623. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection>. Section accessed Sep 12, 2024, Page I-16-17.
624. Camargo JF, Anderson AD, Rosa R, Kimble E, Komanduri KV, Morris MI. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. *Transpl Infect Dis*. 2019 Apr;21(2):e13054. doi: 10.1111/tid.13054. Epub 2019 Feb 11. PubMed PMID: 30689300.
625. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients – Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019;33:e13512
626. Alexander S, Fisher BT, Gaur AH et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation. *JAMA* 2018;320:995-1004
627. Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. *Pediatr Pulmonol* 2012;47(12):1147-58.
628. Allen UD. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. The use of antiviral drugs for influenza: Guidance for practitioners. Oct 9, 2018. Accessed Apr 28, 2022 <https://cps.ca/documents/position/antiviral-drugs-for-influenza>
629. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016;63:e147-95

630. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. *Pediatr Pulmonol* 2013;48(11):1047-61
631. Tomblin M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant* 2009;15:1143-238
632. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. *Antimicrob Agents Chemother*. 2012;56(6):3032-3042
633. Bartelink IH, Wolfs T, Jonker M et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. *Antimicrobial Agents and Chemotherapy* 2013;57:235-40
634. Canadian Paediatric Society Position Statement. Emergency treatment of anaphylaxis in infants and children. *Paediatr Child Health* 2011; 16(1):35-40 (<https://cps.ca/documents/position/emergency-treatment-anaphylaxis>; Reaffirmed Feb 28, 2018)
635. Wenning LA et al. Pharmacokinetics of Famotidine in Infants. *Clin Pharmacokinet* 2005; 44(4): 395-406
636. Orenstein SR et al. Famotidine for Infant Gastro-oesophageal Reflux: a Multi-centre, Randomized, Placebo-controlled, Withdrawal Trial. *Aliment Pharmacol Ther* 2003; 17: 1097-1107
637. Baird DC et al. Diagnosis and Treatment of Gastroesophageal Reflux in Infants and Children. *Am Fam Physician*. 2015 Oct 15;92(8):705-717
638. Sachar H, Vaidya K, Laine L. Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers. *JAMA Internal Medicine* 2014;174:1755
639. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics. *Pediatric Drugs* 2013;15:119–31
640. BCGuidelines.ca: Palliative Care for the Patient with Incurable Cancer or Advanced Disease; Part 2: Pain and Symptom Management – Dyspnea: Appendix A-Medications Used in Palliative Care for Dyspnea and Respiratory Secretions (2017)
641. Jassal SS et al. APPM Master Formulary (5th Edition). The Association of Pediatric Palliative Medicine Master Formulary; 2020, pages 65-66.
642. Hauer J et al. Pediatric Pain and Symptom Management Guidelines. Dana Farber Cancer Institute/Boston Children's Hospital Pediatric Advanced Care Team 2014
643. Health Canada Guidance document - Nonprescription oral adult expectorant cough and cold labelling standard Effective date: 2014/05/30
644. Parisi GF et al. Antihistamines in children and adolescents: A practical update. *Allergol Immunopathol (Madr)*. 2020; 48(6):753-762
645. Anderson S, Farrington E. Magnesium Treatment in Pediatric Patients. *J Ped HC*, 2021; 35(5):564-571
646. Canadian Paediatric Society. Respiratory syncytial virus (RSV) prevention strategies for the 2024-2025 viral respiratory illness season [Internet]. *Cps.ca*. [cited 2024 Dec 28]. Available from: <https://cps.ca/en/documents/position/rsv-prevention-2024-2025>
647. Podpeskar A, Crazzolara R, Kropshofer G, Hetzer B, Rabensteiner E, Meister B, et al. Recommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts. *Nutrients*. 2023 Jul 21;15:3239–9
648. Health Canada Public Advisory, Status of ranitidine drugs in Canada. July 23, 2020. (<https://recalls-rappels.canada.ca/en/alert-recall/status-ranitidine-drugs-canada>)
649. DaSilva J et al. ASPEN Consensus Recommendations for Refeeding Syndrome. *Nutr Clin Prac*. April 2020;35:178
650. Degrassi I, Leonardi I, Elisabetta Di Profio, Montanari C, Gian Vincenzo Zuccotti, Verduci E. Fat-Soluble Vitamins Deficiency in Pediatric Cholestasis: A Scoping Review. 2023 May 26;15:2491–1
651. Abman SH, Hansmann G, Archer SL et al.; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. *Circulation*. 2015 Nov 24;132(21):2037-99. Erratum in: *Circulation*. 2016;133:e368
652. Cartotto R. Topical antimicrobial agents for pediatric burns. *Burns & Trauma* 2017;5:33-40
653. Clouser AA, Merchan CD, Bashqoy F et al. Evaluation of Parenteral Potassium Supplementation in Pediatric Patients. *J Pediatr Pharmacol Ther* 2023;28:48-54
654. Tiddens HAWM et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicenter, randomized, double-blind controlled trial. *Lancet Respir Med*. S2213-2600(21)00546-4. doi: 10.1016/S2213-2600(21)00546-4
655. Nichols KR, Streetman DD, Gordon NA, Knoderer CA. Measurement of polyethylene glycol 3350 with standard household measuring devices. *The Journal of Pediatric Pharmacology and Therapeutics* 2024;29:286–91
656. FDA Drug Safety Communication: FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation [Internet]. U.S. Food and Drug Administration. 2016. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-possible-harm-exceeding-recommended-dose-over-counter-sodium>
657. HIV/HCV Drug Therapy Guide. UHN- Toronto General Hospital, Immunodeficiency Clinic; 2016 [cited 2022 Jan 26]. Available from: <http://app.hivclinic.ca/>
658. ACOG Committee on Adolescent Health Care. Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding. ACOG Committee Opinion No. 785. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2019;134:e71–83
659. Depo-Provera (medroxyprogesterone acetate) [Health Canada Product Monograph]. Pfizer Canada ULC. Kikriand, Quebec. Last revision: December 17, 2021
660. Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. *Obstet Gynecol*. 2006 Oct;108(4):924-9
661. ACOG Committee on Adolescent Health Care. Options for prevention and management of menstrual bleeding in adolescent patients undergoing cancer treatment. ACOG Committee Opinion No. 817. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2021;137:e7–15
662. Unger C. Hormone therapy for transgender patients. *Translational Andrology and Urology*, 2016;5(6):877-884

663. Canadian Paediatric and Adolescent Gynaecology and Obstetricians (CANPAGO) Committee. SOGC Clinical Practice Guideline No. 313-Menstrual Suppression in Special Circumstances. *J Obstet Gynaecol Can* 2019;41(2):e7–e17
664. Diab L, Krebs NF. Vitamin Excess and Deficiency. *Pediatrics in Review*. 2018 Apr;39(4):161–79
665. Williams BA, McCartney H, Singer J, Devlin AM, Vercauteren S, Amid A, et al. Folic acid supplementation in children with sickle cell disease: a randomized double-blind noninferiority cross-over trial. *The American journal of clinical nutrition* [Internet]. 2025 May;S0002-9165(25)000693
666. Protocols for the treatment of hemophilia and von Willebrand disease. 3rd Ed. Georgia. Apr 2008. <http://www1.wfh.org/publication/files/pdf-1137.pdf>
667. Ben-Pazi H. Trihexyphenidyl improves motor function in children with dystonic cerebral palsy: a retrospective analysis. *J Child Neurol*. 2011;26(7):810-816.
668. Carranza-del Rio J, Clegg NJ, Moore A, Delgado MR. Use of trihexyphenidyl in children with cerebral palsy. *Pediatr Neurol*. 2011;44(3):202-206.
669. Rice J and Waugh MC, "Pilot Study on Trihexyphenidyl in the Treatment of Dystonia in Children With Cerebral Palsy," *Child Neurol*, 2009, 24(2):176-82.
670. Sanger TD, Bastian A, Brunstrom J, et al, "Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia Due to Cerebral Palsy," *J Child Neurol*, 2007, 22(5):530-7.
671. Gilead Science Canada Inc VEKLURY Product Monograph, Health Canada April 22, 2022 https://pdf.hres.ca/dpd_pm/00065539.PDF
672. US Food and Drug Administration (FDA) Emergency Use Authorization Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of VEKLURY (remdesivir) https://www.samc.com/assets/documents/covid19/nursing/remdesivir_eua-hcp-fact-sheet-8-2020.pdf accessed May 2 2022
673. Rosenberg JB, Eisen LA. Eye care in the intensive care unit: Narrative review and meta-analysis. *Crit Care Med* 2008;36:3151-3155.
674. Soothe Lubricant Eye Ointment Night Time Dry Eye Therapy [Internet]. 2019 [cited 2020 Aug 11]. Available from: <https://www.sootheeyedrops.com/products/night-time.html>
675. Isopto Tears 0.5% [package insert]. ON, CAN; Alcon Canada Inc.; 2016
676. Isopto Tears 1% [package insert]. ON, CAN; Novartis Pharmaceuticals Canada Inc.; 2017
677. Tear-Gel Ophthalmic Liquid Gel [package insert]. QC, CAN: Bausch & Lomb Inc.; no publication date
678. Tears Plus [product packaging]. ON, CAN: Allergan; 2014
679. Refresh Polyvinyl Alcohol 1.4% Preservative Free. ON, CAN: Allergan; 2019
680. Clinical Guidelines: Care of Children with Cystic Fibrosis – Royal Brompton Hospital. 9th edition. 2023. Accessible at www.rbht.nhs.uk/childrencf
681. Turck D et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children and adults with cystic fibrosis. *Clin Nutr*. 2016;35:557-577
682. Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, Ashwal S, et al. Evidence-based guideline update: Medical treatment of infantile spasms. *Neurology*. 2012;78(24):1974-80
683. Heiskala H, Riikonen R, Santavuori P, Simell O, Airaksinen E, Nuutila A, et al. West syndrome: individualized ACTH therapy. *Brain Dev*. 1995;18(6):456-60
684. Amoxicillin Sodium and Potassium Clavulanate for Injection [product monograph]. Boucherville, Quebec (CA): Sandoz Canada Inc; 2020 [updated 2023 Jan 26; cited 2023 Mar 03]. Available from: https://pdf.hres.ca/dpd_pm/00069325.PDF
685. Carlier M, Noë M, De Waele JJ, et al. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. *J Antimicrob Chemother*. 2013 Jun 25;68:2600-2608
686. Child J, Chen X, Mistry RD, Somme S, MacBrayne C, Anderson PL, et al. Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. *J Pediatric Infect Dis Soc* 2019;8:297-302
687. Lee JY, Ally S, Kelly B, Kays D, Thames L. Once Daily Dosing of Ceftriaxone and Metronidazole in Children With Perforated Appendicitis. *The Journal of Pediatric Pharmacology and Therapeutics* 2016;21:140–145
688. Bowden CL, Janicak PG, Orsulak P et al. Relation of serum valproate concentration to response in mania. *The American Journal of Psychiatry* 1996;153:765-70 Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. *Ther Drug Monit*. 2012 Feb;34(1):77-84
689. Yip L, Aeng E, Elbe D. Management of acute agitation and aggression in children and adolescents with pro re nata oral immediate release antipsychotics in the pediatric emergency department. *J Child Adol Psychopharmacol* 2020;30:534-41
690. Nakamura Y, Takeuchi H, Okuyama K et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. *Transplant Proc*. 2005 May;37:1725-7
691. SUBLOCADE® Buprenorphine extended-release injection. [Health Canada Product Monograph. Indivior UK Limited, Hull UK; Pharma Importing Inc. Toronto ON. Last revision: July 5 2022
692. Kutlu NO, Yakinci C, Dogrul M, et al. Intranasal midazolam for prolonged convulsive seizures. *Brain Devel* 2000;22:359-61
693. Riva A, Lapadre G, Grasso EA, et al. Intramuscular midazolam for treatment of status epilepticus. *Expert Opin Pharmacother* 2021;22(1)37-44
694. Marino B et al. *Circulation* 2018;137:e691-782
695. Ben & Tamara McKenzie. AMAX4 [Internet]. Accessed on March 7, 2025. Available at [AMAX4 | Just a routine resuscitation](https://www.amax4.com/just-a-routine-resuscitation)
696. Coughlin CR et al. Consensus Guidelines For the Diagnosis and Management of Pyridoxine-Dependent Epilepsy Due to α-Aminoacidic Semialdehyde Dehydrogenase Deficiency. *J Inher Metab Dis*. 2021;44:178-192. DOI: 10.1002/jimd.12332
697. CHEO. Preparing for a lower endoscopy. [Internet]. 2019 Dec. Available from: <https://www.cheo.on.ca/en/resources-and-support/resources/P5666E.pdf>

698. Boster AL, Bennett SE, Bilsky GS, Gudesblatt M, Koelbel SF, McManus M, Saulino M. Best Practices for Intrathecal Baclofen Therapy: Screening Test. *Neuromodulation*. 2016 Aug;19(6):616-22.
699. Baclofen injection product monograph. Hikma Canada Limited. May 18, 2022
700. Menon J, Thapa BR, Kumari Ret al. Efficacy of oral psyllium in pediatric irritable bowel syndrome. *J Pediatr Gastroenterol Nutr* 2022;76:14–9
701. Pringsheim T, Panagiotopoulos C, Davidson J et al. CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. *J Can Acad Child Adolesc Psychiatry* 2011;20:218-233
702. Dvorak CC, Fisher BT, Esbenshade AJ et al. A randomized trial of caspofungin vs triazoles prophylaxis for invasive fungal disease in pediatric allogeneic hematopoietic cell transplant. *J Pediatric Infect Dis Soc* 2021;10:417-25
703. Kroll P. Pharmacotherapy for pediatric neurogenic bladder. *Paediatr Drugs* [Internet]. 2017 [cited 5 Nov 2024];19:463-78
704. Stein R, Bogaert G, Dogan HS et al. EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. *Neurourol Urodyn* [Internet]. 2020 [cited 5 Nov 2024];39(1):45-57
705. Lee AS, Viseshsindh W, Long CJ. How early is early? Effect of oxybutynin on bladder dynamics within the first year of life in patients with spina bifida. *J Pediatr Urol* [Internet]. 2020 [cited 5 Nov 2024];16(2):168.e1-6
706. Laza R, Keisler M, Handy V et al. Management of iron infusion reactions. *J Hematol Oncol Pharm* 2023;13:323-7
707. Anvi T, Bieber A, Grossman A et al. The safety of intravenous iron preparations: systematic review and meta-analysis. *Mayo Clinic Proceedings* 2015;90:12-23
708. Glucagon Product Monograph. Eli Lilly Canada Inc. Toronto ON. July 2012
709. BCCH Pediatric Nephrology Program. Childhood Nephrotic Syndrome- a physician's handbook. 2nd ED. February 2017
710. Shulman RJ, Hollister EB, Cain K et al. Psyllium fiber reduces abdominal pain in children with irritable bowel syndrome in a randomized, Double-Blind trial. *Clin Gastroenterol Hepatol* 2016;15:712-719
711. Cogley K, Echevarria A, Correa C, De La Torre-Mondragón L. Contact Burn with Blister Formation in Children Treated with Sennosides. *Pediatric Dermatology* 2017;34(2).
712. Noergaard M, Andersen JT, Jimenez-Solem E, Christensen MB. Long term treatment with stimulant laxatives – clinical evidence for effectiveness and safety? *Scandinavian Journal of Gastroenterology* 2019;54:27–34
713. Ferry GD, Kirschner BS, Grand RJ et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis. *J Pediatr Gastroenterol Nutr* 1993;17:32–8
714. Dahl M, Feldman JL, Goldberg J, Jaber A. Endocrine therapy for transgender adults in British Columbia: Suggested guidelines. 2015. Vancouver Coastal Health
715. Sanofi-Aventis Canada Inc. Resonium Calcium® Product Monograph. 19 July 2022
716. Warady BA, Barcia J, Benador N, et al. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 2018; 33:125-37
717. Bruce G, Schulga P, and Reynolds BC. Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review. *Clin Kidney J* 2022; 15(8):1483-1505
718. Thomas J, Stonebrook E, and Kallash M. Pediatric hypertension: Review of the definition, diagnosis, and initial management. *Int J Pediatr Adolesc Med* 2022; 9:1-6
719. Concerns about children's medication [Internet]. www.canada.ca. 2010. Available from: <https://www.canada.ca/en/health-canada/services/drugs-medical-devices/concerns-about-children-s-medication.html>
720. Prochlorazine (prochlorperazine) Prescribing Information [Internet]. AA Pharma Inc 2012. Accessed Mar 20, 2025 Available from: https://pdf.hres.ca/dpd_pm/00034858.PDF
721. SUDAFED SINUS ADVANCE® | SUDAFED® | Canada [Internet]. Sudafed.ca. 2025 [cited 2025 Mar 18]. Available from: <https://www.sudafed.ca/products/pressure-pain/sudafed-sinus-advance>
722. Overview of dietary trace elements. UpToDate [Internet]. Uptodate.com Accessed Mar 21, 2025. Available from: <https://www.uptodate.com>
723. Park SW, Yi YY, Han JW, Kim HD, Lee JS, Kang HC. Wernicke's encephalopathy in a child with high dose thiamine therapy. *Korean Journal of Pediatrics*. 2014;57(11):496
724. Hassan SA, Gupta V. Maple Syrup Urine Disease [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557773/>
725. Dry Cough Syrup for Children | BENYLIN® Canada [Internet]. Benylin.ca. 2025 [cited 2025 Mar 18]. Available from: <https://www.benylin.ca/products/children/dry-cough-syrup>
726. Zhou P, Jia Q, Wang Z, Zhao R, Zhou W. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis. *Front Pediatr*. 2022 Aug 25;10:940213
727. De-Regil LM, Jefferds MED, Sylvestsky AC, Dowswell T. Intermittent Iron Supplementation for Improving Nutrition and Development in Children under 12 Years of Age. *Cochrane Database of Systematic Reviews*. 2011 Dec 7;(12).
728. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, Melse-Boonstra A, Brittenham G, Swinkels DW, Zimmermann MB. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. *Blood*. 2015; 126 (17): 1981–1989
729. Patel A, Le K, Panek N. Evaluation of valganciclovir's neutropenia risk in pediatric solid organ transplant recipients utilizing two dosing regimens. *Pediatric Transplantation* 2024;28:e14714
730. BC Children's Hospital PediCrisis Checklists. Jul 21, 2022. Accessed Apr 3, 2025. Available from: https://shop.healthcarebc.ca/phsa/BCWH_2/Pharmacy.%20Therapeutics%20and%20Nutrition/C-05-07-60317.pdf
731. BC Children's Hospital Management of Traumatic Brain Injury in Children with GCS <8. Dec 20, 2021. Accessed Apr 3, 2025. Available from: https://shop.healthcarebc.ca/phsa/BCWH_2/Pharmacy.%20Therapeutics%20and%20Nutrition/C-05-07-62754.pdf
732. Payne RM, Burns KM, Glatz AC et al. Apixaban for prevention of thromboembolism in pediatric heart disease. *J Am Coll Cardiol* 2023;82:2296-2309

733. VandePluym C, Estes P, Ankola A et al. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. *J Thromb Haemost* 2023;21:1601-9
734. Mole C et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. *Lancet Haematol* 2019;7:e18-27
735. Xarelto (rivaroxaban) Full Prescribing Information. FDA. Revised 01/2022. Accessed Mar 27, 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022406s039_202439s038lbl.pdf#page=77
736. Thrombosis Canada. Clinical Guidelines. DOACs: Perioperative Management. Accessed Apr 4, 2025 Available at: https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guidelID=PERIOPERATIVEMANAGEMENTOFPATIE
737. Azer SM, Goldfarb DS. A summary of current guidelines and future directions for medical management and monitoring of patients with cystinuria. *Healthcare (Basel)* 2023;11:674
738. Bhatt NP, Despande AL, Starkey MR. Pharmacological interventions for the management of cystinuria: a systematic review. *J Nephrol* 2024;37:293-308
739. Servais A, Thomas K, Dello Strologo L et al. Cystinuria: clinical practice recommendation. *Kidney Int* 2021;99:48-58
740. Gianolio L, Emmitt S, Nwabueze M et al. Initial effectiveness and safety data on intravenous ferric derisomaltose for iron deficiency anaemia management in paediatric gastroenterology patients: a multicentre retrospective cohort study. *Arch Dis Child* 2025;0:1-7
741. McMahon S, Gupta R, Zak E et al. A retrospective single-center study of ferric derisomaltose in adolescent patients. *Pediatr Blood Cancer* 2025
742. Child J, Chen X, Mistry RD et al. Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. *J Pediatric Infect Dis Soc* 2019;8:297-302
743. Tzield® P. TZIELD (Teplizumab for injection) Product Monograph Including Patient Medication Information [Internet]. [cited 2025 Nov 26]. Available from: https://pdf.hres.ca/dpd_pm/00080446.PDF
744. Mehta S, Ryabets-Lienhard A, Patel N et al. Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice. *Horm Res Paediatr* 2025;98:597-608
745. Gitelman SE, Simmons K, Sher JL et al. Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes. *Diabetologia* 2025 <https://doi.org/10.1007/s00125-025-06586-1>
746. Herold KC, Gitelman SE, Gottlieb PA et al. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β -Cell Function. *Diabetes Care* 1 October 2023;46:1848-1856
747. O'Neil ER, Schmees LR, Resendiz K, et al. Inhaled tranexamic acid as a novel treatment for pulmonary hemorrhage in critically ill pediatric patients: an observational study. *Crit Care Explor* 2020;2(1):e0075
748. Merchant A, Lazarus R, Thompson C, et al. Use of nebulized tranexamic acid in adult patients with cystic fibrosis: a retrospective audit. *Respir Med* 2025;245:108187
749. Schoettler ML, Dandoy CE, Harris A, et al. Diffuse alveolar hemorrhage after hematopoietic cell transplantation – response to treatments and risk factors for mortality. *Front Oncol* 2023;13:1232621
750. Kim S, Rush BS, Rice TR. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. *Eur Child Adolesc Psychiatry* 2021;30:1485-1501
751. Dwyer JB, Landeros-Weisenberger A, Johnson JA et al. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. *Am J Psychiatry* 2021;178:352-362